＜競争的資金＞

研究代表者

1. 日本医療研究開発機構（AMED）医薬品等規制調和・評価研究事業．国内マスタープロトコル試験の実施に関する規制的、統計的、実務的課題の検討とその適正利用のためのガイドライン作成（研究代表者）．2023（R5）年度〜2025（R7）年度．

2. 日本医療研究開発機構（AMED）研究開発推進ネットワーク事業．臨床試験を主導する研究者の育成を含む臨床試験支援体制の構築と運用．（研究代表者）．2021（R3）年度〜2021（R3）年度．

3. 日本医療研究開発機構（AMED）医薬品等規制調和・評価研究事業 医薬品・医療機器・再生医療等製品等に係るレギュラトリーサイエンスに関する研究．希少疾患領域の医薬品開発を効率化するための小規模臨床試験のデザイン・統計解析法の研究開発とその適正利用のための基本的考え方の策定．（研究代表者）．2019（R1）〜2021（令和3）年度．

4. 日本医療研究開発機構（AMED）認知症対策官民イノベーション実証基盤整備事業．認知症に対する非薬物療法のエビデンス創出に資するデータ品質一元管理センターの基盤構築と継続的研究支援のための体制整備．（研究代表者）.2019（R1）〜2022（令和4）年度．

5. 日本学術振興会 科学研究費 基盤研究（C）．バスケット型臨床試験における治療効果の異質性評価のための統計的方法論の研究開発．（研究代表者）.2020（R2）年度〜2022（R4）年度．

6. 日本学術振興会 科学研究費 基盤研究（C）．がん分子標的薬の長期毒性データに基づく新規ベイズ流用量探索デザインの研究開発．（研究代表者）.2017（H29）年度〜2019（H31）年度．

7. 日本学術振興会 科学研究費 若手研究（B）．がん分子標的薬の特性を考慮したベイズ流用量探索法の研究開発．（研究代表者）．2015（H27）年度〜2017（H29）年度．

8. 日本学術振興会 科学研究費 若手研究（B）．抗がん剤併用療法のための縮小回帰に基づく用量探索法の研究．（研究代表者）．2013（H25）年度〜2014（H26）年度．

9. 中部科学技術センター 学術症例研究助成事業．癌患者ビッグデータに基づく癌分子標的薬の新たな効果の探索と同定．（研究代表者）．2015（H27）年度．

10. 工藤学術財団 学術研究補助．がんゲノムデータに基づく疾患予後・治療効果予測法の開発に関する基盤研究．（研究代表者）．2014（H26）年度．

11. 聖ルカ・ライフサイエンス研究所 臨床疫学等に関する研究助成金．臨床疫学・生物統計学・レギュラトリーサイエンスに関するメディカル・スタッフ向け教育プログラムの開発．（研究代表者）．2014（H26）年度．

＜教科書＞

Book

1. **Hirakawa A**, Sato H, Daimon T, Matsui S. *Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted*, Springer. 2018. Springer.

2. Daimon T, **Hirakawa A,** Matsui S. *Dose-Finding Designs for Early Phase Cancer Clinical Trials*, 2019, Springer.

Book chapter

3. **Hirakawa A**, Matsui S. (2014). Dose-finding for two-agent combination phase I trials. *Developments in Statistical Evaluation of Clinical Trials*, Springer.

4. Daimon T, **Hirakawa A**, Matsui S. (2014). Phase I dose-finding designs and their applicability to targeted therapies. *Design and Analysis of Clinical Trials for Predictive Medicine*, CRC Press.

5. **Hirakawa A,** Sato H. (2017) A comparative study of model-based dose-finding methods for two-agent combination trials. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*, Springer.

6. 前田圭介（編著）．室谷健太（編著）．(2020) 生存時間データの分析．*臨床研究アウトプット術,* 中外医学社

7. 平川晃弘, 佐藤宏征．臨床試験のデザインと統計解析．内田一郎、芹生卓（編集）．(2022) 製薬医学入門：くすりの価値最大化をめざして．メディカンル・サイエンス・インターナショナル

8. 平川晃弘，マスタープロトコルに基づく臨床試験．丹後 俊郎・松井 茂之（編）．臨床試験の事典．朝倉書店．2023.

翻訳

9. 五所正彦（監訳）．佐藤泰憲，竹内久朗，長島健悟，中水流嘉臣，平川晃弘（共訳），松永信人，山田雅之．生存時間解析入門 [原著第 2 版]．デビッド・ホスマー，スタンリー・レメショウ，スーザン・メイ Applied Survival Analysis, 2nd edition. 2014．東京大学出版会．

10. 西山毅（監訳）．菱田朝陽，中栃昌弘，室谷健太，平川晃弘（共訳）．実践でわかる！ R による統計遺伝学. Andrea S. Foulkes．2016．丸善出版．

11. 平川晃弘（監訳）．浅野淳一，上村鋼平，佐藤宏征，木下文恵，武内亜希子（共訳）．臨床試験のためのデータモニタリング委員会：実践ハンドブック．スーザン・エレンバーグ，トーマス・フレミング，デビット・デメッツ．Data Monitoring Committees in Clinical Trials: A Practical Perspective. 2017．サイエンティスト社．

12. 平川晃弘，五所正彦（監訳）．臨床試験のためのアダプティブデザイン．2018．朝倉書店．

<査読付論文＞

Biostatistics and Data Science

1. Mizusawa J, Sato H, Rubinstein L V, Fujiwara T, Yonemori K, **Hirakawa A (corresponding author)**. Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials. *Cancer Medicine*, 00:1-12, 2023

2. Hanazawa R, Sato H, Sasaki M, Suzuki K, **Hirakawa A (corresponding author)**. Study designs and statistical analyses in randomized controlled trials of non-pharmacological preventive and therapeutic interventions for dementia continuum: A statistical review. *Dementia Japan,*37(1):96-132, 2023

3. Asano J, Sato H, **Hirakawa A (corresponding author)**. Practical basket design for binary outcomes with control of family-wise error rate. *BMC Medical Research Methodology,* 23:52, doi: https://doi.org/10.1186/s12874-023-01872-1, 2023

4. **Hirakawa A**, Sato H, Hanazawa R, Suzuki K; Japanese Alzheimer's Disease Neuroimaging Initiative. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. *Statistics in Medicine*. 41(21):4200-4214, doi: 10.1002/sim.9504. 2022.

5. **Hirakawa A**, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. *Pharmaceutical Statistics*, 21: 691-695, 2022.

6. Kawatsu Y, Tsuchida J, Ando S, **Hirakawa A**, Sozu T. Sample size determination in phase I oncology trials based on selection probability of the maximum tolerated dose. *Japanese Journal of Biometrics,* 42(1) 55-64, doi: 10.5691/jjb.42.55*,* 2021.

7. Kaneko S, **Hirakawa A (corresponding author)**. Assessment of overall treatment effect in the presence of inconsistent regional effects in multiregional clinical trials. *Statistics in Biopharmaceutical Research.* doi:10.1080/19466315.2021.1845233,2020

8. Asano J, **Hirakawa A (corresponding author)**. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. *Pharmaceutical Statistics 2020* 19(6):975-1000,2020

9. Kaneko S, **Hirakawa A**, Kakurai Y, Hamada C. A dose-finding approach for genomic patterns in phase I trials. *Journal of Biopharmaceutical Statistics*. 2020.

10. **Hirakawa A**, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. *Clinical Pharmacology & Therapeutics*. 106:803-809, 2019.

11. Kakurai Y, Kaneko S, Hamada C, **Hirakawa A (corresponding author).** Dose individualization

and variable selection using Bayesian Lasso in early phase dose-finding trials. *Applied Statistics*. 68:445-460, 2019.

12. Kada A, **Hirakawa A (co-first author)**, Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. *Contemporary Clinical Trials Communications*. 14: 100316, 2019.

13. **Hirakawa A**, Tanaka Y, Kaneko S. Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. *Contemporary Clinical Trial Communications*. https://doi.org/10.1016/j.conctc.2019.100489, 2019.

14. **Hirakawa A**, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. *Contemporary Clinical Trial Communications*, 12:1-8, 2018.

15. **Hirakawa A**, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: study protocol for a randomized controlled trial. *Trials*. 19 :510, 2018.

16. Shimamura F, Hamada C, Matsui S, **Hirakawa A (corresponding author)**. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. *Journal of Biopharmaceutical Statistics*, 18:1-13, 2018.

17. **Hirakawa A**, Yonemori K, Kinoshita F, Kobayashi Y, Okuma H. Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trial. *Cancer Science*, 109:207-214, 2018.

18. **Hirakawa A**, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. *Therapeutic Innovation & Regulatory Science*, 52:334-338, 2018.

19. Nomura S, **Hirakawa A**, Hamada C. Sample size determination for the current strategy in oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. *Journal of Biopharmaceutical Statistics*, 8: 1-23, 2017.

20. Gosho M, Maruo K, Tada K, **Hirakawa A**. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. *European Journal of Clinical Pharmacology*, 73: 779-786, 2017.

21. Shimura M, Gosho M, **Hirakawa A**. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. *Statistics in Medicine,* 36:2067-2080, 2017.

22. **Hirakawa A,** Kinoshita F. An analysis of Japanese patients enrolled into multiregional clinical

trials in oncology. *Therapeutic Innovation & Regulatory Science*, 51: 207–211, 2017.

23. Asano J, <u>**Hirakawa A** (co-first author)</u>. Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. *Journal of Biopharmaceutical Statistics*, 1-15, doi: 10.1080/10543406.2017.1293082, 2017 Feb 13.

24. Gosho M, Maruo K, Ishii R, <u>**Hirakawa A.**</u> Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. *Statistical Methods in Medical Research*, DOI: 10.1177/0962280216677879, 2016.

25. <u>**Hirakawa A**</u>, Sato H, Gosho M. Effect of design specifications in dose-finding trials for combination therapies in oncology. *Pharmaceutical Statistics*, 15: 531-540, 2016.

26. ○Sato H, <u>**Hirakawa A (co-first author)**</u>, Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. *Statistics in Medicine*, 35:4093-4109, 2016.

27. Yonemori K, <u>**Hirakawa A (co-first author)**</u>, Kawachi A, Kinoshita F, Ohkuma H, Nishikawa T, Kenji T, Fujiwara Y, Takebe N. Drug induced Interstitial Lung Disease in Oncology Phase I Trials. *Cancer Science*, 107(12):1830-1836, 2016.

28. <u>**Hirakawa A**</u>, Sato H. Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. *Statistics in Medicine*, 35: 479-480, 2016.

29. Gosho M, <u>**Hirakawa A**</u>, Maruo K, Noma H, Sato Y. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts. *Statistical Method in Medical Research*, doi: 10.1177/0962280215597938, 2015.

30. <u>**Hirakawa A**</u>, Wages NA, Sato H, Matsui S. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. *Statistics in Medicine*, 34: 3194-3213, 2015.

31. <u>**Hirakawa A**</u> and Matsui S. Operating characteristics of restrictions on skipping dose level for adaptive dose-finding method in two-agent phase I trials. *Japanese Journal of Biometrics*, 36:1-12, 2015.

32. Kakurai Y, <u>**Hirakawa A**</u>, Hamada C. A dose-finding method based on multiple dosing in two-agent combination phase I trials. *Journal of Biopharmaceutical Statistics*, 25:1065-1076, 2015.

33. Kaneko S, <u>**Hirakawa A**</u>, Hamada C. Enhancing the lasso approach for developing a survival prediction model based on gene expression data. *Computational and Mathematical Methods in Medicine*, 2015: 259474, 2015.

34. <u>**Hirakawa A**</u>, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. *Current Drug Safety*, 9: 220-226, 2014.

35. Asakawa T, <u>**Hirakawa A**</u>, Hamada C. Bayesian model averaging continual reassessment method

for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. *Journal of Biopharmaceutical Statistics*, 23:310-325, 2014.

36. Asano J, **Hirakawa A**, Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. *Pharmaceutical Statistics*, 13:357-363, 2014.

37. **Hirakawa A**, Matsui S. Response to Letter to the Editor by Drs Wages et al. *Statistics in Medicine*, 33:2159-60 2014.

38. Asano J, **Hirakawa A**, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. *Japanese Journal of Biometrics*, 34: 21-34, 2013.

39. **Hirakawa A**, Hamada C, Matsui S. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. *Statistics in Medicine*, 32:4515-4525,2013

40. **Hirakawa A**. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. *Statistics in Medicine*, 31:516-532, 2012.

41. Kaneko S, **Hirakawa A**, Hamada C. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. *Cancer Informatics*, 11: 29-39, 2012.

42. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. *Journal of Biopharmaceutical Statistics*, 22:260-275, 2012.

43. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. *Statistics and Probability Letters*, 81:870-875, 2011.

44. Ando Y, **Hirakawa A**. Discussion of "Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations". *Statistics in Biopharmaceutical Research*, 2: 462-465, 2010.

45. Ando Y, **Hirakawa A**, Uyama Y. Adaptive clinical trials for new drug applications in Japan. *European Neuropsychopharmacology,* 21: 175-179, 2010.

46. **Hirakawa A**, Sato Y, Hamada C, Yoshimura I. A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experiments. *Bioinformatics and Biology Insights*, 2:145-156, 2008.

47. **Hirakawa A**, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identifying differentially expressed genes in microarray data analysis. *Cancer Informatics*, 3:367-375, 2007.

Cooperative Clinical and Basic Researches

48. Mori M, Yoshizaki K, Watabe S, Ishige M, Hinoki A, Kondo T, Taguchi T, Hasegawa H, Hatata

T, Tanuma N, Kirino N, **Hirakawa A**, Naruto T, Imai M, Koike R, Hosoi K, Kusudao S. Safety, efficacy and pharmacokinetics of Palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: A multicenter phase II clinical trial, 39:100847. 2023

49. Yamaguchi Y, Tanaka H, Kimura K, Fukuda S, Fukushima H, Waseda Y, Yoshida S, Yokoyama M, **Hirakawa A**, Tateishi U, Campbell S C, Fujii Y. Prognostic impact of the radiological infiltrative feature of primary renal tumor in metastatic renal cell carcinoma. *International Journal of Urology,* doi.org/10.1111/iju.15234. 2023

50. Hirai S, **Hirakawa A**, Fujita K, Ishiwada T, Sasaki M, Yoshimura M, Shigeta K, Sato Y, Yamada K, Ishikawa M, Sagawa H, Aoyama J, Fujii S, Ishii Y, Sawada K, Obata Y, Karakama J, Hara M, Kawano Y, Nemoto S, Sumita K. Imaging predictors of clinical outcomes after endovascular treatment in MRI-selected patients with acute basilar artery occlusion. *Clinical Neurology and Neurosurgery,* 231:107824, doi: 10.1016/j.clineuro.2023.107824. 2023

51. Yokoi A, Ukai M, Yasui T, Inokuma Y, Kim H D, Matsuzaki J, Yoshida K, Kitagawa M, Chattrairat K, Iida M, Shimada T, Manabe Y, Chang I Y, Asano-Inami E, Koya Y, Nawa A, Nakamura K, Kiyono T, Kato T, **Hirakawa A**, Yoshida Y, Ochiya T, Hasegawa T, Baba Y, Yamamoto Y, Kajiyama H.   Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. *Science Advances,* 9(27): eade6958 doi: 10.1126/sciadv.ade6958. 2023

52. Nakamura R, Tohnai G, Nakatochi M, Atsuta N, Watanabe H, Ito D, Katsuno M, **Hirakawa A**, Izumi Y, Morita M, Hirayama T, Kano O, Kanai K, Hattori N, Taniguchi A, Suzuki N, Aoki M, Iwata I, Yabe I, Shibuya K, Kuwabara S, Oda M, Hashimoto R, Aiba I, Ishihara T, Onodera O, Yamashita T, Abe K, Mizoguchi K, Shimizu T, Ikeda Y, Yokota T, Hasegawa K, Tanaka F, Nakashima K, Kaji R, Niwa J, Doyu M, Terao C, Ikegawa S, Fujimori K, Nakamura S, Ozawa F, Morimoto S, Onodera K, Ito T, Okada Y, Okano H, Sobue G, on behalf of the Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS) study group. Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients. *Journal of Neurology, Neurosurgery & Psychiatry*, 94(10):816-824, doi. org/ 10. 1136/ jnnp- 2022-330851. 2023

53. Hosoya T, Oba S, Komiya Y, Kawata D, Kamiya M, Iwai H, Miyamoto S, Kataoka M, Tobiume M, Kanno T, Ainai A, Sato H, **Hirakawa A**, Mitui Y, Satoh T, Wakabayashi K, Yamada T, Otomo Y, Miyazaki Y, Hasegawa H, Suzuki T, Yasuda S. Apple-shaped obesity; a risky soil for cytokine-accelerated severity in COVID-19. *Proc Natl Acad Sci USA,* 30;120(22): e2300155120 doi: 10.1073/pnas.2300155120. 2023

54. Unuma K, Sato H, Wen S, Makino Y, **Hirakawa A**, Uemura K. The proportion of false-positives

in positive Seratec® prostate-specific antigen SemiQuant test results in postmortem screening for seminal fluid. *Legal Medicine.* 62;102243. doi: 10.1016/j.legalmed.2023.102243. 2023

55. Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, **Hirakawa A**, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). *BMC Urology.* 23(1):33, doi: 10.1186/s12894-023-01202-z. 2023

56. Ohara M, Hirata K, Hallett M, Matsubayashi T, Chen Q, Kina S, Shimano K, **Hirakawa A**, Yokota T, Hattori T. Long term levodopa ameliorates sequence effect in simple, but not complex walking in early Parkinson's disease patients. *Parkinsonism & Related Disorders.* 108:105322 doi: 10.1016/j.parkreldis.2023.105322. 2023

57. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Okubo M, Kamiya H, **Hirakawa A**, Kawasaki M, Kondo T, Suzuki T, Matsuo H. Diagnostic Accuracy of Artificial Intelligence-Based Angiography-Derived Fractional Flow Reserve Using Pressure Wire-Based Fractional Flow Reserve as Reference. *Circulation Journal.* 87(6): 783-790. doi: 10.1253/circj.CJ-22-0771. 2023

58. Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, **Hirakawa A**, Nakamura K, Yonemori K. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. *Journal of Clinical Oncology,* 41(15):2789-2799, doi: 10.1200/JCO.22.02558. 2023

59. Hattori T, Ohara M, Yuasa T, Azuma R, Chen Q, Hanazawa R, **Hirakawa A**, Orimo S, Yokota T. Callosal angle at splenium correlates with gait and cognition in normal pressure hydrocephalus. *Journal of Neurosurgery.* 139(2):481-491. doi: 10.3171/2022.12.JNS221825. 2023

60. Shitara K, Kawazoe A, **Hirakawa A**, Nakanishi Y, Furuki S, Fukuda M, Ueno Y, Raizer J, Arozullah A. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. *Cancer Science.* 114(4):1606-1615. Doi: 10.1111/cas.15684. 2023

61. Takenaka K, Kitazume Y, Kawamoto A, Fujii T, Udagawa Y, Watanabe R, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Sato H, **Hirakawa A**, Watanabe M, Okamoto R. Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Transmural Inflammation in Crohn's Disease. *American Journal of Gastroenterology.* 118(6):1028-1035. doi: 10.14309/ajg.0000000000002127. 2023

62. Inagaki T, Hashizume A, Hijikata Y, Yamada S, Ito D, Kishimoto Y, Torii R, Sato H, **Hirakawa**

A, Katsuno M. Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy. *Scientific Reports*. 12(1):17443. doi: 10.1038/s41598-022-22322-w. 2022

63. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, **Hirakawa A**, Shimizu S, Nakamura T, Katsuno M. Mexiletine in Spinal and Bulbar Muscular Atrophy: A Randomized Controlled Trial. *Annals of Clinical and Translational Neurology*. 9(11):1702-1714. doi: 10.1002/acn3.51667. 2022

64. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, **Hirakawa A**, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. *Front Oncol.* 11, doi: 10.3389/fonc.2021.732525. 2021

65. Sakaki K, Yoshii T, Arai Y, Torigoe I, Tomori M, Onuma H, Ogawa T, **Hirakawa A**, Sakai K, Okawa A. Effectiveness of Lumbosacral Orthosis after Discectomy for Lumbar Disc Herniation: A Prospective Comparative Study. *Spine,* doi:10.1097/BRS. 0000000000004475,2022

66. Kotani T, Imai K, Ushida T, Moriyama Y, Nakano-Kobayashi T, Osuka S, Tsuda H, Sumigama S, Yamamoto E, Kinoshita F, **Hirakawa A**, Iwase A, Kikkawa F, Kajiyama H. Pregnancy Outcomes in Women with Thyroid Diseases. JMA journal 2022

67. Oda G, Nakagawa T, Mori H, Onishi I, Fujioka T, Mori M, Kubota K, Hanazawa R, **Hirakawa A**, Ishikawa T, Okamoto K, Uetake H. Factors predicting upstaging from clinical N0 to pN2a/N3a in breast cancer patients. *World Journal of Clinical Oncology,* 13(9):748-757,doi:10.5306/wjco.v13.i9.748, 2022

68. Takahashi Y, Yamamoto T, Oyama J, Sugihara G, Shirai Y, Tao S, Takigawa M, Sato H, Sasaki M, **Hirakawa A**, Takahashi H, Goya M, Sasano T. Increase in Cerebral Blood Flow after Catheter Ablation of Atrial Fibrillation. *JACC: Clinical Electrophysiology,* doi:10.1016/j.jacep.2022.07.011, 2022

69. Murata K, Takahashi Y, Inaba O, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Sato H, Hanazawa R, **Hirakawa A**, Goya M, Sasano T. Efficacy of Left Atrial Posterior Wall Isolation Guided by Lesion Size Prediction Module for Non-paroxysmal Atrial Fibrillation. *EP Europace,* euac079, (2022) 00 1–8, doi: 10.1093/europace/euac079, 2022.

70. Nakayama K, Shachar S, Finn E H, Sato H, **Hirakawa A**, Misteli T. Large-scale mapping of positional changes of hypoxia-responsive genes upon activation. *Molecular Biology of the Cell,* 33(8): ar72. doi: 10.1091/mbc.E21-11-0593, 2022

71. Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, **Hirakawa A**, Hayakawa M, Sato Y. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised,

dose-escalation trial. BMJ OPEN, 12(4): e057073,doi: 10.1136/bmjopen-2021-057073, 2022

72. Inose H, Kato T, Sasaki M, Matsukura T, Sasaki M, Matsukura Y, Hirai T, Yoshii T, Kawabata S, **Hirakawa A**, Okawa A. Comparison of decompression, decompression plus fusion, and decompression plus stabilization: a long-term follow-up of a prospective, randomized study. *The Spine Journal,* 22(5)747-755. doi: 10.1016/j.spinee.2021.12.014, 2021

73. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, **Hirakawa A**, Yamada S. Neuromuscular electrical stimulation mitigates muscle weakness in elderly diabetic patients after cardiovascular surgery, *Annals of Physical and Rehabilitation Medicine,* 7;101659, doi: 10.1016/j.rehab.2022.101659, 2022

74. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, **Hirakawa A**, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. *Frontiers in Cardiovascular Medicine,* doi: 10.3389/fcvm.2021.767074, 2021

75. Noda-Narita S, Kawachi A, Okuyama A, Sadachi R, **Hirakawa A**, Goto Y, Fujiwara Y, Higashi T, Yonemori K. First-line treatment for lung cancer among Japanese older patients: a real-world analysis of hospital-based cancer registry data. *PLOS ONE,* 16(9): e0257489. doi: 10.1371/journal.pone.0257489, 2021

76. Yamada S, Hashizume A, Hijikata Y,Ito D, Kishimoto Y, Iida M, Koike H, **Hirakawa A**, Katsuno M. Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. *Journal of Neurology,Neurosurgery & Psyychiatry,* jnnp-2020-324615. doi: 10.1136/jnnp-2020-324615,2021

77. Ezaki A, **Hirakawa A**, Hanaoka H, Uyama Y. Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis. *Therapeutic innovation & regulatory science,* doi: 10.1007/s43441-021-00309-5,2021

78. Sugimoto T, Sakurai T, Akatsu H, Doi T, Fujiwara Y, **Hirakawa A**, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Arai H, J-MINT investigators. The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial. *The Journal of Prevention of Alzheimer's Disease,* doi:10.14283/jpad.2021.29,2021.

79. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Inaba O, Murata K, Sasaki Y, Yoshimoto D, Kaneko M, Tanimoto Y, Isogai R, Yamashita S, Sato H, Hanazawa R, **Hirakawa A,** Goya M, Sasano T. Alcohol Consumption

Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation. *Circulation:Arrhythmia and electrophysiology, 14(6):e009770.* doi:10.1161/circep.121.009770, 2021

80. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, **Hirakawa A**, Suzuki T, Kondo T, Leipsic J, NØrgaard B L, Matsuo H. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived From CTA Using Pressure Wire Assessment as Reference. *American Journal of Roentgenology,* 216:1492-1499 doi: 10.2214/AJR.20.24090,2021

81. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, **Hirakawa A**, Koike R, Kusuda S. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. *BMC Pediatrics,* 21(1):106. doi: 10.1186/s12887-021-02567-6,2021

82. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Kawamura I, Okubo M, Kamiya H, **Hirakawa A**, Kawasaki M, Nakagawa M, Tsuchiya K, Suzuki Y, Ito T, Terashima M, Kondo T, Suzuki T, Escaned J, Matsuo H. Comparisons of Nonhyperemic Pressure Ratios: Predicting Functional Results of Coronary Revascularization Using Longitudinal Vessel Interrogation. *JACC. Cardiovascular interventions,*13(22):2688-2698.doi: 10.1016/j.jcin.2020.06.060,2020

83. Ushida T, Kotani T, Hayakawa M, **Hirakawa A**, Sadachi R, Nakamura N, Moriyama Y, Imai K, Nakano-Kobayashi TmKikkawa F. Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. *Scientific reports,*10(1):9312. Doi: 10.1038/s41598-020-66242-z, 2020

84. Kimura K, Itoh Y, Okada T, Kubota S, Kawamura M, Nakahara R, Oie Y, Kozai Yuka, Takase Y, Tsuzuki H, Nishio N, Hiramatsu M, Fujimoto Y, Mizutani T, **Hirakawa A**, Naganawa S. Study Protocol: Prospective study of concurrent chemoradiotherapy with S-1 and hypofractionated radiotherapy for outpatients with early glottic squamous cell carcinomas Asian Pacific Journal of Cancer Prevention, 19:1195-1999, 2018

85. Kato M, **Hirakawa A**, Sato H, Hanazawa R, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Grade group 2 (10%≥GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. *International Journal of Clinical Oncology*, 2021, doi: 10.1007/s10147-020-01841-4.

86. Kato M, **Hirakawa A**, Kobayashi Y, Yamamoto A, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. *International Journal of Clinical Oncology*, 25(12):2130-2137. 2020.

87. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, **Hirakawa A**, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. *Stem cells translational medicine.* 2021. doi: 10.1002/sctm.20-0381.

88. Yokoi K, Hattori M, Satake Y, Tanaka Y, Sato M, Hashizume A, Hori A, Kawashima M, **Hirakawa A**, Watanabe H, Katsuno M. Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. *Scientific Reports*, 25;10(1):20524, 2020

89. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito M A, **Hirakawa A**, Kiyoi H, Matsumura I, Miyazaki Y, Japan Adult Leukemia Study Group. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: A phase 1/2 dose- escalation study by the Japan Adult Leukemia Study Group. *International Journal of Hematology* 2021. doi: 10.1007/s12185-020-03032-3.

90. Ikenouchi T, Inaba O, Takamiya T, Inamura Y, Sato A, Matsumura Y, Sato H, **Hirakawa A**, Takahashi Y, Goya M, Sasano T, Nitta J. The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation. *American Heart Journal*, 231:82-92, 2021.

91. Kuwatsuka Y, Atsuta Y, **Hirakawa A**, Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. *International Journal of Hematology*, 112(6):841-850, 2020.

92. Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, **Hirakawa A**, Tateishi U, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). *Medicine (Baltimore)*. 99(32):e21457, 2020.

93. Kitase Y, Sato Y, Arai S, Onoda A, Ueda K, Go S, Mimatsu H, Jabary M, Suzuki T, Ito M, Saito A, **Hirakawa A**, Mukai T, Nagamura-Inoue T, Takahashi Y, Tsuji M, Hayakawa M. Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells. *Frontiers in Cellular Neuroscience*. 14:212, 2020.

94. Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Nakayama S, Kuwatsuka Y, Mizuno M, **Hirakawa A**. Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived

regenerative cells: Outcome of the ADRESU study. *International Journal of Urology*. 27(10):859-865, 2020.

95. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, **Hirakawa A**, Motoi T, Sakai T, Kobayashi E, Gokita T, Okamoto T, Matsunobu T, Shimizu K, Koike H. Risk Factors of Local Recurrence after Surgery in Extra-Abdominal Desmoid-Type Fibromatosis: A Multicenter Study in Japan. *Cancer Science*. 111(8):2935-2942, 2020.

96. Ushida T, Kotani T, Sadachi R, **Hirakawa A**, Hayakawa M, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F, for the Neonatal Research Network of Japan. Antenatal Corticosteroids and Outcomes in Preterm Twins. *Obstetrics and Gynecology.*135:1387-1397, 2020.

97. Majima S, Wakahara K, Nishio T, Nishio N, Teranishi M, Iwano S, **Hirakawa A**, Hashimoto N, Sone M, Hasegawa Y. Bronchial wall thickening is associated with severity of chronic rhinosinusitis. *Respiratory Medicine*. 170:106024, 2020.

98. Kawachi A, Yamashita S, Okochi-Takada E, **Hirakawa A**, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. *Breast Cancer Research and Treatment.* 181:323-329. 2020.

99. Kato T, Motoji Y, Tamaki M, Inagaki M, Tsunekawa T, **Hirakawa A**, Okawa Y, Tomita S. Clinical benefits of fast-track rehabilitation program for patients with uncomplicated type B acute aortic dissection. *General Thoracic and Cardiovascular Surgery*. 68(11):1234-1239, 2020

100. Suzuki K, **Hirakawa A**, Ihara R, Iwata A, Ishii K, Ikeuchi T, Chung-KaiSun, Donohue M, Iwatsubo T. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Intervention*s, 6(1):e12007, 2020.

101. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, **Hirakawa A**, Soen S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) *Journal of Bone and Mineral Metabolism*. 38(4):522-532, 2020.

102. Kawase Y, Omori H, Tanigaki T, **Hirakawa A**, Hirata T, Ota H, Kikuchi J, Sobue Y, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. In vivo validation of resting full-cycle ratio and diastolic pressure ratio - simultaneous measurement with instantaneous wave-free ratio. *Cardiovascular Intervention and Therapeutics*, doi: 10.1007/s12928-020-00648-4, 2020.

103. Hattori M, Tsuboi T, Yokoi K, Tanaka Y, Sato M, Suzuki K, Arahata Y, Hori A, Kawashima M, **Hirakawa A**, Washimi Y, Watanabe H, Katsuno M. Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. *Journal of Neurology*, 267(5):1516-1526; 2020.

104. Okuma HS, Yonemori K, Narita SN, Sukigara T, **Hirakawa A**, Shimizu T, Shibata T, Kawai A,

Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers through a Platform Trial. *Clinical Pharmacology & Therapeutics*, 108(3):596-605, 2020.

105. Nishizawa M, Onodera O, **Hirakawa A**, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. *Journal of Neurology, Neurosurgery & Psychiatry*, 91:254-262; 2020.

106. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, **Hirakawa A**, Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. *Journal of Bone and Mineral Metabolism*, 38(4):511-521, 2020.

107. Kato M, **Hirakawa A**, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. *The Prostate*, 80:284-290; 2020.

108. Sakakibara S, Hashimoto R, Katayama T, Kenjyo M, Yokokawa Y, Saito Y, **Hirakawa A**, Ito M, Nakamura T, Hara K, Hashizume A, Aiba I, Inukai A, Katsuno M. Longitudinal change of DAT SPECT in Parkinson's disease and multiple system atrophy. *Journal of Parkinson's Disease.* 10(1):123-130, 2020.

109. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, **Hirakawa A**, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. *Journal of Neurology*, 266(12):2952-2961, 2019.

110. Hirata T, Tanigaki T, Kawase Y, **Hirakawa A**, Omori H, Okamoto S, Ota H, Sobue Y, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Pijls NHJ, Matsuo H. Post-occlusional hyperemia for fractional flow reserve assessment and pull-back curve analysis. *Cardiovascular Intervention and Therapeutics*, 35(2):142-149, 2020.

111. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T, Araki A, Hijikata Y, **Hirakawa A**, Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. *Journal of Neurology*, 266:1211-1221, 2019.

112. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, **Hirakawa A**, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. *Translational Psychiatry*, 9: 126, 2019.

113. Shimizu S, Tsuchiya S, **Hirakawa A**, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H.. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in

Japan: the TEOM study protocol. *BMC Oral Health*, 19:69, 2019.

114. Kato M, **Hirakawa A,** Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. *Prostate*, doi:10.1002/pros.23818, 2019.

115. Takano N, Yamada S, **Hirakawa A**, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. *Nagoya Journal of Medical Science*, 81:233-239, 2019.

116. Yokoyama T, Miyahara R, Funasaka K, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Hirooka Y, **Hirakawa A**, Goto H. The utility of ultrathin endoscopy with flexible spectral imaging color enhancement for early gastric cancer. *Nagoya Journal of Medical Science*, 81:241-248, 2019.

117. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, **Hirakawa A**, Takahashi Y, Sato Y, Natsume J. Comparison of clinical characteristics of human metapneumovirus and respiratory syncytial virus infection in hospitalized young children. *Japanese Journal of Infectious Diseases*, 72: 237-242, 2019.

118. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, **Hirakawa A**, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. *Neurology*, 92: e1868-e1877, 2019.

119. Maeda T, Sato Y, **Hirakawa A**, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. *Nagoya Journal of Medical Science*, 81:227-232, 2019.

120. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, **Hirakawa A**, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. *European Journal of Cancer*, 109: 84-91, 2019.

121. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, **Hirakawa A**, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-

Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. *Frontiers in Neurology*, 9: 987, 2018.

122. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, **Hirakawa A**, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). *BMJ Open*, 8: e021759, 2018.

123. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, **Hirakawa A**, Nakamura T, Katsuno M. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). *BMJ Open*, 8: e023041, 2018.

124. Tsunekawa T, Sawada M, Kato T, Motoji Y, Kinoshita T, **Hirakawa A**, Okawa Y, Tomita S. The prevalence and distribution of occlusive lesions of the cerebral arteries in patients undergoing coronary artery bypass graft surgery; Seminars in Thoracic and Cardiovascular Surgery; 2018, 30(4):413-420.

125. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, **Hirakawa A**, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a Semiconductor Camera: Comparison with the Rest-Stress 99mTc-Tetrofosmin Protocol. *Circulation Journal*, 82: 2837-2844, 2018.

126. Kato M, **Hirakawa A**, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. *Modern Pathology*, 32:122-127, 2019.

127. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, **Hirakawa A**, Wakabayashi T. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. *World Neurosurgery*, 118: e818-e824, 2018.

128. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, **Hirakawa A**, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. *Clinica Chimica Acta*, 484: 192-196, 2018.

129. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, **Hirakawa A**, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The rate of neonatal respiratory distress syndrome/transient tachypnea in the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton

pregnancies. *Clinica Chimica Acta*, 484: 293-297, 2018.

130. Tanaka R, Yonemori K, **Hirakawa A**, Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. *The Oncologist*, 24: 266-272, 2019.

131. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, **Hirakawa A**, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. *Medicine*, 97(17): e0449, 2018.

132. Ohsawa Y, Hagiwara H, Nishimatsu SI, **Hirakawa A**, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. *Journal of Neurology, Neurosurgery, and Psychiatry*, pii: jnnp-2018-317964. doi: 10.1136/jnnp-2018-317964, 2018.

133. Imai K, Kotani T, Nakano T, Ushida T, **Hirakawa A**, Kikkawa F. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. *The Journal of Maternal-Fetal & Neonatal Medicine*, 28:1-5, 2018 Feb.

134. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, **Hirakawa A**, Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial. *PLOS ONE*, 13(2):e0192688, 2018.

135. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, **Hirakawa A**, Tateyama H, Yokoi K. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group. *European Journal of Cardio-Thoracic Surgery*, 49: 574-579, 2016.

136. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, **Hirakawa A**, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. *Journal of Cardiology*, 71(5):458-463, 2018 May.

137. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, **Hirakawa A**, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Hori A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. *Neurology*, 90(17): e1501-e1509, 2018.

138. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, **Hirakawa A**, Kinoshita F, Gosho M, Sobue G. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: study protocol for a randomized, double-blind, placebo-controlled trial. *JMIR*

Research Protocol, 7(3): e69, 2018.

139. Miyauchi R, Itoh Y, Kawamura M, **Hirakawa A**, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. *Nagoya Journal of Medical Science*, 79(2):211-220. doi: 10.18999/nagjms.79.2.211, 2017 Feb.

140. Miyamoto K, Ohkawara B, Ito M, Masuda A, **Hirakawa A**, Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling. *PLoS One*, 12: e0184388, 2017.

141. Sawamura A, Okumura T, **Hirakawa A**, Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study. *Circulation Journal*, doi: 10.1253/circj.CJ-17-0549, 2017.

142. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, **Hirakawa A**, Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer. *International Journal of Clinical Oncology*, doi: 10.1007/s10147-017-1219-6, 2017.

143. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, **Hirakawa A**, Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study. *Epilepsia*, doi: 10.1111/epi.13988, 2018.

144. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, **Hirakawa A**, Suzuki T, Matsuo H. Postocclusional hyperemia for fractional flow reserve after percutaneous coronary intervention. *JACC-Cardiovascular Interventions*, 10. doi: 10.1161/CIRCINTERVENTIONS.117.005674, 2017.

145. Kato M, Kimura K, **Hirakawa A**, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation. *Prostate*, 78: 11-16, 2018.

146. Shimizu S, Yamamoto T, Nakayama S, **Hirakawa A**, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol. *BMC Urology*, 17: 89, 2017.

147. Yokoi A, Yoshioka Y, **Hirakawa A**, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer. *Oncotarget*, 8: 89811-89823, 2017.

148. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K,

Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, **<u>Hirakawa A</u>**, Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. *Endoscopy International Open*, 5: E1136-E1143, 2017.

149. Kawase Y, Tanigaki T, **<u>Hirakawa A</u>**, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers. *Cardiovascular Intervention and Therapeutics*, doi: 10.1007/s12928-017-0481-x, 2017.

150. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, **<u>Hirakawa A</u>**, Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. *Archives of Disease in Childhood*, doi: 10.1136/archdischild-2016-311403, 2017.

151. Hashizume A, Katsuno M, Suzuki K, **<u>Hirakawa A</u>**, Hijikata Y, Yamada S, Inagataki T, Banno M, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy -Natural history-controlled study- *Journal of Neurology, Neurosurgery, and Psychiatry*, 88: 1026-1032, 2017.

152. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, **<u>Hirakawa A</u>**, Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma, *European Journal of Cardio-Thoracic Surgery*, 52:969-974, doi:10.1093/ejcts/ezx124, 2017.

153. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, **<u>Hirakawa A</u>**, Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique. *Neurologia Medico-Chirurgica*, 57:238-245, 2017.

154. Nakanishi K, Sato Y, Mizutani Y, Ito M, **<u>Hirakawa A</u>**, Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats. *Scientific Reports,* 7:44111, 2017.

155. Kato T, Tamaki M, Tsunekawa T, Motoji Y, **<u>Hirakawa A</u>**, Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms. *Heart Vessel,* doi: 10.1007/s00380-017-0956-9, 2017.

156. Imai K, Kotani T, Tsuda H, Nakano T, **<u>Hirakawa A</u>**, Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound. *Ultrasound in medicine and biology,* 43(3):615-620, 2017.

157. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, **<u>Hirakawa A</u>**, Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G. Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. *PLoS One*, 11(12): e0168846, 2016.

158. Yamasaki S, **<u>Hirakawa A</u>**, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. *Annals of Hematology*, 96(2):289-297, 2017.

159. Kato T, Tsunekawa T, Motoji Y, **<u>Hirakawa A</u>**, Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit. *Heart and Vessels*, 32(4):385-389, 2017.

160. Suzuki N, **<u>Hirakawa A</u>**, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. *Haemophilia*, 23(2):215-221, 2017.

161. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, **<u>Hirakawa A</u>**, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. *Annals of Clinical and Translational Neurology*, 3: 537-546, 2016.

162. Atsuta Y, **<u>Hirakawa A</u>**, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, 22: 1702-1709, 2016.

163. Okuma H, Koizumi F, **<u>Hirakawa A</u>**, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. *British Journal of Cancer*, 115: 411-419, 2016.

164. Yokoi D, Atsuta N, Watanabe H, Nakamura R, **<u>Hirakawa A</u>**, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. *Journal of Neurology*, 263: 1129-1136, 2016.

165. Harano K, **<u>Hirakawa A</u>**, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. *Gynecologic Oncology*, 141: 447-453, 2016.

166. Nagata T, Sobajima H, Ohashi N, **<u>Hirakawa A</u>**, Katsuno T, Yasuda Y, Matsuo S, Tsuboi N, Maruyama S. Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR

More than 30 ml/min/1.73m2. *PLOS ONE*, 11: e0152306, 2016.

167. Yamada S, Fujii T, **Hirakawa A**, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. *Langenbeck's Archives of Surgery*. 401(8):1143-1152, 2016.

168. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, **Hirakawa A**, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. *Leukemia*, 30: 1568-1579, 2016.

169. Tanaka R, Yonemori K, **Hirakawa A**, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoin treatment with bone-modifying agents. *Oncologist*, 21: 508-513, 2016.

170. Kato M, Tsuzuki T, Kimura K, **Hirakawa A**, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. *Modern Pathology*. 29: 166-73, 2016.

171. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, **Hirakawa A**, Gotoh M. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. *Urology*. 88: 149-154, 2016.

172. Imai K, Kotani T, Tsuda H, Mano Y, Nakano T, Ushida T, Li H, Miki R, Sumigama S, Iwase A, **Hirakawa A**, Ohno K, Toyokuni S, Takeuchi H, Mizuno T, Suzumura A, Kikkawa F. Neuroprotective potential of molecular hydrogen against perinatal brain injury via suppression of activated microglia. *Free Radical Biology & Medicine*, 91: 154-163, 2016.

173. ○Watanabe H, Atsuta N, **Hirakawa A (co-first author)**, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. *Journal of Neurology, Neurosurgery, and Psychiatry*, 87: 851-858, 2016.

174. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, **Hirakawa A**, Tateyama H, Yokoi K. Prognostic impact of tumour size in completely resected thymic epithelial tumours. *European Journal of Cardio-Thoracic Surgery*, 49: 574-579, 2016.

175. Harano K, Yonemori K, **Hirakawa A**. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. *Breast Cancer*, 23: 797-806, 2016.

176. Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y,

Iwase A, **Hirakawa A**, Asai M, Toyokuni S, Kikkawa F. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury. *Journal of Clinical Biochemistry and Nutrition*, 57: 178-182, 2015.

177. Harano K, **Hirakawa A**, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. *International Journal of Clinical Oncology*, 21: 168-176, 2016.

178. Tsuda H, **Hirakawa A**, Kotani T, Sumigama S, Mano Y, Nakano T, Imai K, Kawabata I, Takahashi Y, Iwagaki S, Kikkawa F. Risk assessment for neonatal RDS/TTN using gestational age and the amniotic lamellar body count in twin pregnancies. *Clinica Chimica Acta*. 451: 301-304, 2015.

179. Suzuki N, Takedani H, **Hirakawa A**, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX®). *Haemophilia*, 21: 702-707, 2015.

180. Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, **Hirakawa A**, Yokoi K. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma? *Lung Cancer*, 89: 38-42, 2015.

181. Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, **Hirakawa A**, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study, *Neuromuscular Disorders*, 25: 554-562, 2015.

182. Okada N, Tajima K, Takami Y, Kato W, Kei F, Hibino M, Munakata H, Sakai Y, **Hirakawa A**, Usui A. Valve selection for the aortic position in dialysis patients. *The Annals of Thoracic Surgery*; 99: 1524-1531, 2015.

183. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T, Hirata H, **Hirakawa A**, Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. *Developmental Neuroscience*, 37: 95-104, 2015.

184. Kato T, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, **Hirakawa A**, Yokoi K. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. *General Thoracic and Cardiovascular Surgery*, 63: 343-348, 2015.

185. Tsuda H, Kotani T, Sumigama S, Mano Y, Kawabata I, Takahashi Y, Iwagaki S, **Hirakawa A**, Kikkawa F. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies. *Clinica Chimica Acta*, 441: 75-78, 2015.

186. ○Watanabe H, Atsuta N, Nakamura R, **Hirakawa A (co-first author)**, Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda

M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 16: 230-236, 2015.

187. Kataoka Y, Nishida S, **Hirakawa A**, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. *Endocrine Journal*, 62: 195-200, 2015.

188. Ozeki N, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, **Hirakawa A**, Yokoi K. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer. *Interactive Cardiovascular and Thoracic Surgery*, 5:830-837, 2014.

189. Taniyama TK, Hashimoto K, Katsumata, N, **Hirakawa A**, Yonemori K, Yunokawa M,S himizu C,Tamura K, Ando M, Fujiwara Y. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? *Current Oncology*, 21: 84-90, 2014.

190. Harano K, **Hirakawa A**, Kato T, Suzuki K, Watanabe S, Katsumata N. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan. *Journal Gynecologic Oncology*, 25: 124-129, 2014.

191. Yamada S, **Hirakawa A**. Reply to: appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer. *Surgery*, 155: 959-960, 2014.

192. Arima H, Wakabayashi T, Nagatani T, Fujii M, **Hirakawa A**, Murase T, Yambe Y, Yamada T, Yamakawa F, Yamamori I, Yamaguchi M, Oiso Y. Adipsia increases risk of death in patients with central diabetes insipidus. *Endocrine Journal*, 61:143-148, 2014.

193. Goto M, Yamamoto T, Kato M, Majima T, Toriyama K, kamei Y, Matsukawa Y, **Hirakawa A**, Funahashi Y. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients. *International Journal of Urology*, 21: 294-300, 2014.

194. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, Sakao Y, Mitsudomi T, **Hirakawa A**, Yokoi K. Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small cell lung cancer. *European Journal of Cardio-Thoracic Surgery*, 45: 687-692, 2014.

195. Asano J, **Hirakawa A**, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox's cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy. *International Journal of Breast Cancer*, 354579, 2013.

196. Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, **Hirakawa A**, Yokoi K.

Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the TNM classification of lung cancer. *Journal of Thoracic Oncology*, 8: 1551-1557, 2013.

197. Nakamura R, Atsuta N, Watanabe H, **Hirakawa A**, Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Izumi Y, Morita M, Ogaki K, Taniguchi A, Aiba I, Mizoguchi K, Okamoto K, Hasegawa K, Aoki M, Kawata A, Abe K, Oda M, Konagaya M, Imai T, Nakagawa M, Tsuji S, Kaji R, Nakano I, Sobue G. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. *Journal of Neurology, Neurosurgery, and Psychiatry*, 84:1365-1371, 2013.

198. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, **Hirakawa A**, Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS. *PLoS ONE*, 25: e66969, 2013.

199. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, **Hirakawa A**, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia. *Cell Death & Disease*, 7: e525, 2013.

200. Sato Y, Kawataki M, **Hirakawa A**, Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates. *Acta Paediatrica*, 102: e241-e246, 2013.

201. Tanabe Y, Hashimoto K, Shimizu C, **Hirakawa A**, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. I*nternational Journal of Clinical Oncology*, 18: 132-138, 2013.

202. Azuma Y, Hata K, Sai K, Udagawa R, **Hirakawa A**, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. *Biological & Pharmaceutical Bulletin*, 35: 717-724, 2012.

203. Kojima Y, Hashimoto K, Ando M, **Hirakawa A**, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. *Journal of Cancer Research and Clinical Oncology*, 138: 1249-1257, 2012.

204. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. *PLoS ONE*, 7: e44393, 2012.

205. Yonemori K, **Hirakawa A**, Ryushima Y, Saito M, Yamamotoro H, Hirata T, Ando M, Kodaira

M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara. An analysis of guidance for proper usage documents for oncology drugs in Japan. *Pharmaceutical Medicine*, 26: 165-170, 2012.

206. Hashimoto K, Sasajima Y, Ando M, Yonemori K, **Hirakawa A**, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma. *PLoS ONE*, 7: e31181, 2012.

207. Hashimoto K, Yonemori K, Katsumata N, **Hirakawa A**, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 159: 394-398, 2011.

208. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious "drug lag" for oncology in Japan. *Investigational New Drugs*, 29: 706-712, 2011.

209. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? *Journal of Geriatric Oncology*, 2: 25-30, 2011.

210. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Compliance with good clinical practice in oncology registration trials in Japan. *Annals of Oncology*, 22: 1451-1456, 2011.

211. Hirata T, Yonemori K, **Hirakawa A**, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. *European Respiratory Journal*, 38: 1425-1430, 2011.

212. Hirata T, Yonemori K, Ando M, **Hirakawa A**, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma. *European Journal of Dermatology*, 21: 539-545, 2011.

213. Yonemori K, Tsuta K, Ando M, **Hirakawa A**, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. *Annals of Surgical Oncology*, 18: 2841-2850, 2011.

214. Hashimoto K, Yonemori K, Shimizu C, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. *Medical Oncology*, 28: 434-440, 2011.

215. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, **Hirakawa A**, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. *Annals of Oncology*, 21:

2195-2200, 2010.

216. Yonemori K, **Hirakawa A**, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registration trials for oncology drug applications in Japan. *Annals of Oncology*, 21: 2112-2118, 2010.

217. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, **Hirakawa A**, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. *Journal of Surgical Oncology*, 101: 222-227, 2010.

218. Yonemori K, Kouno T, Ando M, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary non-seminomatous germ cell tumor. *Oncology*, 78: 34-39, 2010.

219. Yonemori K, Tsuta K, Ono M, Shimizu C, **Hirakawa A**, Hasegawa T, Hatanaka Y, Narita T, Shibui S, Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer. *Cancer*, 116: 302-308, 2010.

220. Hirata T, Shimizu C, Yonemori K, **Hirakawa A**, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. *British Journal of Cancer*, 101: 1529-1536, 2009.

221. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, **Hirakawa A**, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. *British Journal of Cancer*, 100: 50-55, 2008.

＜査読付論文＞

Review

1. 橋詰 公一，武田 健太朗，佐藤 宏征，平川晃弘，寒水 孝司. がん第 1 相用量探索試験におけるモデル支援型デザインの最近の展開，43(1):3-36, 2022.

2. 平川晃弘，浅野淳一，佐藤宏征，橋本大哉，手良向聡. がん臨床試験におけるベイズ流バスケットデザインの理論と実装. 計量生物学， 39: 103-122, 2019.

3. 平川晃弘，浅野淳一，佐藤宏征，手良向聡. マスタープロトコルに基づくがん臨床試験. 計量生物学，39: 85-101, 2019.

4. 平川晃弘，松井茂之. がん第 I 相試験における 2 剤併用療法の用量探索法：最近の展開. 計量生物学，34: 81-97, 2013.

Regulatory Science

5. 平川晃弘，佐藤 宏征，井桁 正尭，藤川 桂，堀口 剛，大門 貴志，手良向 聡. 希少疾患

領域の治験におけるベイズ流アプローチの利用可能性と留意事項． *薬理と治療 Jpn Pharmacol Ther* 2021; 49(s1): s72-79.2021

6. <u>平川晃弘</u>，木下文恵，森由美子，清水忍．抗悪性腫瘍薬の臨床データパッケージ分析からみる今後の課題． *医薬品医療機器レギュラトリーサイエンス*,46:714-720, 2015.

7. 斉藤真理，龍島靖明，米盛勧，<u>平川晃弘</u>，文靖子，西垣玲奈，牧野好倫，岩瀬治雄，安藤正志，藤原康弘，林憲一．製薬企業発行の抗悪性腫瘍薬剤患者説明用パンフレットの現状調査． *日本病院薬剤師会雑誌*, 51: 877-881, 2015

8. 安藤友紀，<u>平川晃弘</u>．サロゲートエンドポイントの課題と展望〜薬事行政の立場から〜． *医薬ジャーナル*, 47: 73-75, 2011

Cooperative Clinical and Basic Researches

9. <u>平川晃弘</u>，生存時間データの統計解析． *医学のあゆみ*，280(5): 290-395, 2022

10. <u>平川晃弘</u>，佐藤宏征. 生存時間解析． *Journal of Clinical Rehabilitation,* 30(9): 977-981, 2021

11. 大熊ひとみ，<u>平川晃弘</u>，米盛勧． MASTER KEY プロジェクトー希少がんに対するレジストリ・バスケット臨床研究. 腫瘍内科, 22:435-442, 2019

12. 大熊ひとみ，<u>平川晃弘</u>，米盛勧. 希少がんに対する新薬開発の取り組みと課題~MASTER KEY プロジェクト~． 血液内科. 76:806-812, 2018.

13. 大熊ひとみ，<u>平川晃弘</u>，米盛勧，川井章. MSTER KEY プロジェクト． がん分子標的治療． 16:16-20, 2018;

14. 小川 千香子，三浦 清邦，伊藤 祐史，城所 博之，<u>平川晃弘</u>，根来 民子，夏目 淳. 重症心身障害児を持つ親の離婚． *日本小児科学会雑誌*. 121:563, 2017.

15. 伊藤祐史，三浦清邦，原紳也，岸本泰明，<u>平川晃弘</u>，小川千香子，城所博之，奥村直哉，梶田光春，夏目淳. 重度肢体不自由児の救急外来受診と入院医療.*日本小児科学会雑誌*. 120: 356-366, 2016.

＜国際学会発表＞

1. Arai H, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, **<u>Hirakawa A</u>**, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Sakurai T, J-MINT study group. The Japan-multimodal intervention trial for prevention of dementia (J-MINT): a multi-center, randomized, 18-month controlled trial. AAIC 2023, July 16-20, 2023

2. Tsuchiya K, Nagahori M, Hanazawa R, Sasaki S, Sato H, **<u>Hirakawa A</u>**, Anzai T, Takahashi K, Kobayashi Y, Hibiya S, Takenaka K, Watanabe M. Serial daily recording of patient-reported outcomes (PRO2) might predict treatment change in the patients with ulcerative colitis. ECCO2023, Mar 1-4, 2023.

3. Uemura Y, Yamamoto M, Ishimura M, Kanegane H, Sawada A, **<u>Hirakawa A</u>**, Imadome K,

Yoshimori M, Nagata M, Shimizu N, Koike R, Arai A. Phase II Study of a JAK1/2 Inhibitor Ruxolitinib for Systemic Chronic Active Epstein-Barr Virus Disease: An Investigator-Initiated Trial. ASH, Dec 10-13, 2022 December

4. Sato H, Sasaki M, **Hirakawa A**.　Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents. 2022 WNAR Annual Meeting, 13 June 2022, Online.

5. Ikeda S, Kudo R, Yamashita Y, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Tateishi U, **Hirakawa A**, Akita H, Matsubara H, Nishihara H, Ishioka C, Sueoka-Aragane N, Muto M, Toyooka S. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. ASCO, Jun 3-7, 2022.

6. Arakawa A, Ozawa H, **Hirakawa A**, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando R, Terashima K, Nakamura K, Ogawa C. A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors. ASCO, Jun 3-7, 2022.

7. Kojima Y, Shimizu T, Yonemori K, Koyama T, Matsui N, Kamikura M, Tomatsuri S, Sumiyoshi Okuma H, Shimoi T, Noguchi E, Sudo K, **Hirakawa A**, Sadachi S, Okita N, Nakamura K, Yamamoto N, Fujiwara Y. A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with a highly life-threatening unmet needs（NCCH1806/MK004）, ESMO Congress 2021, 16-21 September 2021, Online.

8. Hasegawa K, Nishikawa T, **Hirakawa A**, Kawasaki M, Tomatsuri S, Nagasaka Y, Nakamura K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Yoshida H, Yonemori K. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL. ESMO Congress 2021, 16-21 September 2021, Online.

9. Kudo R, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Akita H, Matsubara H, Nishihara H, Ishioka C, Aragane N, Muto M, Toyooka S,[1] Tateishi U, **Hirakawa A**, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). ASCO, June 4-8, 2021, Online.

10. Kawai A, Nishikawa T, Kawasaki M, Tomatsuri S, Okamura N, Ogawa G, **Hirakawa A**, Shibata T, Nakamura K, Kakunaga S, Tamura K, Ando M, Ozaki T, Ueda T, Yonemori K. Efficacy and Safety of Nivolumab Monotherapy in Patients with Unresectable Clear Cell Sarcoma and Alveolar Soft Part Sarcoma (OSCAR t rial, NCCH1510): A Multicenter, Phase 2 Clinical Trial OSCAR. CTOS 2020 Annual Meeting. November 18-21, 2020, Online.

11. Asano J, **<u>Hirakawa A</u>**. An Empirical Bayesian Basket Trial Design Accounting for Uncertainties of Homogeneity and Heterogeneity of Treatment Effect among Subpopulations. ENAR 2020 Spring Meeting, March 22-25, 2020, Nashville, USA.

12. Tanaka Y, Sozu T, **<u>Hirakawa A</u>**. Dose-Finding Method for Molecularly Targeted Agents Incorporating the Relative Dose Intensity in Phase I Oncology Clinical Trials. ENAR 2019 Spring Meeting, March 24-27, 2019, Philadelphia, USA.

13. Sadachi R, **<u>Hirakawa A</u>**. Heterogeneity Assessment of Treatment Effect among Subpopulations in Basket Trials. ENAR 2019 Spring Meeting, March 24-27, 2019, Philadelphia, USA.

14. **<u>Hirakawa A</u>**, Sadachi R. A Basket Trial Design using Bayesian Model Averaging. ENAR 2019 Spring Meeting, March 24-27, 2019, Philadelphia, USA.

15. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, **<u>Hirakawa A</u>**, Sakai T, Shimizu K, Kobayashi E, Gokita T, Okamoto T, Matsunobu, T. Significant risk factors of local recurrence after surgery in extra-peritoneal desmoid-type fibromatosis: a multicenter study in Japan. The CTOS 2018 Annual Meeting. November 14-17, 2018, Rome, Italy.

16. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, **<u>Hirakawa A</u>**, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. ESMO, Oct 19 - 23, 2018, Munich, Germany.

17. Asano J, **<u>Hirakawa A</u>**. An evaluation and modification of Simon's basket design in oncology. ISCB ASC 2018. August 26-30, 2018, Melbourne, Australia.

18. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, **<u>Hirakawa A</u>**, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. ASCO, June 1-5, 2018, Chicago, IL.

19. **<u>Hirakawa A</u>**, Kakurai Y, Kaneko S, Hamada C. Dose individualization based on multiple gene mutations for molecularly targeted agents. 37th International Society for Clinical Biostatistics, August 21-25, 2016, Birmingham, UK.

20. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, **<u>Hirakawa A</u>**, Ohashi M, Matsumoto Y, Arioka Y, Oya-Ito T, Kushima I, Nakamura Y, Shiino T, Mori D, Maeda T, Tanaka S, Hamada S, Noma H, Yoshida M, Noda Y, Nagai T, Yamada K, Ozaki N. The development of molecular diagnostic tool for schizophrenia using lymphoblastoid cell lines. US HUPO 2016 Conference, March 13-16, 2016, Boston, MA.

21. **<u>Hirakawa A</u>**. A Data-Driven Clustering Method Using a Mixture Approach of Nonlinear Mixed-Effects Model for Longitudinal Functional Rating Scale in Amyotrophic Lateral Sclerosis Patients. East Asia Regional Biometric Conference 2015, December 20-22, 2015, Fukuoka, Japan.

22. Shimamura F, **<u>Hirakawa A</u>**, Hamada C. Dose Finding Design for Two-Agent Combination Trials. East Asia Regional Biometric Conference 2015, December 20-22, 2015, Fukuoka, Japan.

23. Sato H, **<u>Hirakawa A</u>**, Hamada C. An Adaptive Dose-Finding Method Using a Change-Point Model for Molecularly Targeted Agents in Phase I Trials. East Asia Regional Biometric Conference 2015, December 20-22, 2015, Fukuoka, Japan.

24. Kaneko S, **<u>Hirakawa A</u>**, Hamada C. Establishing Individualized Treatment Rules Based on Bayesian Model Averaging Approach. East Asia Regional Biometric Conference 2015, December 20-22, 2015, Fukuoka, Japan.

25. Shimoi T, Yonemori K, **<u>Hirakawa A</u>**, Kinoshita F, Bun S, Shimomura S, Kodaira M, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. Is there a relationship between oncology drugs' costs and efficacy? European Society for Medical Oncology, September 25-29, 2015, Vienna, Austria.

26. Kawachi A, Yonemori K, **<u>Hirakawa A</u>**, Kinoshita F, Tamura K, Fujiwara Y, Takebe N. Incidence and risk factors in interstitial lung disease in Cancer Therapy Evaluation Program phase I trials. European Society for Medical Oncology, September 25-29, 2015, Vienna, Austria.

27. Yoshimi A, Kunimoto S, Yamada S, Aleksic B, **<u>Hirakawa A</u>**, Nagai T, Ozaki N. JSNP Excellent Presentation Award for CINP2014. Nihon Shinkei Seishin Yakurigaku Zasshi. 2015; 35:59-60.

28. Shimura M, Gosho M, **<u>Hirakawa A</u>**. A comparison of conditional bias-adjusted estimators of a treatment difference for continuous data in group sequential designs. Royal Statistical Society, September 7-10,2015, UK.

29. Asano J, **<u>Hirakawa A</u>**. A novel C-statistic for evaluating prediction accuracy in a cure model for censored survival data with long-term survivors. 36th Annual Conference of the International for Clinical Biostatistics, August 23-27, 2015, Utrecht, Netherlands.

30. Harano K, **<u>Hirakawa A</u>**, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saiot T. Optimal debulking surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group, May 29-June 2, 2015, Chicago, US.

31. Sato H, **<u>Hirakawa A</u>**, Hamada C. Dose-finding approach based on efficacy and toxicity outcomes in phase I oncology trials for molecularly targeted agents. The 2015 ENAR Spring Meet, March 11-15, 2015, Miami, USA.

32. Shimada K, Shimada S, Sugimoto K, Hayakawa F, Katayama M, **<u>Hirakawa A</u>**, Takagi Y, Nakamura S, Seto M, Naoe T, Tomita A, Kiyoi H. Development and analysis of novel intravascular large B-cell lymphoma NOD/Shi-*scid* IL2Rγ[null] mouse xenograft model. The 56th Annual Meeting of the American Society of Hematology, December 6-9, 2014, San Francisco, USA.

33. Yoshimi A, Aleksic B, Kunimoto S, Kushima I, Nakamura Y, Kimura H, Takasaki Y, Wang C, Xing J, **Hirakawa A**, Ikeda M, Iwata N, Ozaki N. Transcriptome analysis of lymphoblastoid cell line from schizophrenia and bipolar disorder. XXII World Congress of Psychiatric Genetics, October 16-20, 2014, Denmark.

34. Kato T, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, **Hirakawa A**, Iwano S, Yokoi K. The contact length between the tumor contour and lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. 28th Annual Meeting of the European Association for Cardio-Thoracic Surgery, October 11-15, 2014, Italy.

35. Asano J, **Hirakawa A**, and Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model. 35th International Society for Clinical Biostatistics, August 24-28, 2014, Austria.

36. Okuma H, Koizumi F, **Hirakawa A**, Nakatochi M, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis . European Society of Medical Oncology, June 25-28, 2014, Spain.

37. Tanaka R, Yonemori K, **Hirakawa A**, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events associated with metastatic breast cancer patients receiving bone-modifying agents. European Society of Medical Oncology, June 25-28, 2014, Spain.

38. Nara E, Yunokawa M, Yonemori K, Doutani C, Shimizu K, Mimaki Y, Oomatsu N, Komatsu M, **Hirakawa A**, Shimizu C, Fujiwara Y, Tamura K. Identifying the social support needs of young cancer patients in Japan. European Society of Medical Oncology, June 25-28, 2014, Spain.

39. Yoshimi A, Kunimoto S, Yamada S, Aleksic B, **Hirakawa A**, Nagai T, Ozaki N. Proteomic analysis of the lymphoblastoid cell line derived from Japanese schizophrenic patients. 29th CINP World Congress of Neuropsychopharmacology, June 22-26, 2014, Canada.

40. Usami N, Yokoi K, Murotani K, **Hirakawa A**, Tabata C, Soejima T, Kamikonya N, Tanaka F, Yamanaka T, Okada M, Hasegawa S, Nakano T. Assessment of postoperative complications after the first all Japan multi-institutional trial of induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.15th World Conference on Lung Cancer, October 27-30, 2013, Australia.

41. Kakurai Y, Sano M, **Hirakawa A**, Hamada C. A dose-finding approach based on cohort partitioning for combination of two agents in Phase I trials in oncology. 34th International Society for Clinical Biostatistics, August 25-29, 2013, Germany.

42. Nomura S, **Hirakawa A**, Hamada C. Sample size calculation for confirming both PFS and OS simultaneously in cancer clinical trials. 34th International Society for Clinical Biostatistics, August 25-29, 2013, Germany.

43. Asano J, **Hirakawa A**, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model. 34th International Society for Clinical Biostatistics, August 25-29, 2013, Germany.

44. Yamada K, **Hirakawa A**, Hamada C. Operating characteristics of the penalized Cox regression analysis in high-dimensional microarray data. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

45. Kaneko S, **Hirakawa A**, Hamada C. Gene selection using a high-dimensional Cox model in microarray data analysis. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

46. Mano H, **Hirakawa A**, Hamada C. Improvement of Trim and Fill method to adjust publication bias in meta-analysis using the clinical trial registration system. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

47. Atsumi J, **Hirakawa A**, Hamada C. A new allocation method for balancing prognostic continuous and categorical variables in clinical trials. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

48. Asakawa T, **Hirakawa A**, Hamada C. A dose-finding method using bayesian model averaging for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

49. Asano J, **Hirakawa A**, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

50. **Hirakawa A**, Hamada C. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

51. **Hirakawa A**, Hamada C. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. XXVIth International Biometrics Conference, August 26-31, 2012, Kobe, Japan.

52. Asano J, **Hirakawa A**, Hamada C. A stepwise variable selection for a cure model. 3rd East Asia Regional Biometric Conference, February 2-3, 2012, Seoul, Korea.

53. Kaneko S, Yamada K, **Hirakawa A**, Hamada C. Estimating the false positive rate in a high-dimensional regression model in cancer prognostic studies with microarrays. 3rd East Asia Regional Biometric Conference, February 2-3, 2012, Seoul, Korea.

54. **Hirakawa A**, Hamada C. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. 3rd East Asia Regional Biometric Conference, February 2-3, 2012, Seoul, Korea.

55. **Hirakawa A**, Kaneko S, Hamada C. Gene selection using a high-dimensional Cox model in microarray data analysis. Pacific Symposium on Biocomputing, January 3-7, 2012, Big Island of Hawaii.

56. Yonemori K, **Hirakawa A**, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yamamoto H, Fujiwara Y. Content analysis of "the guidance for proper usage" that are distributed to medical oncologists for promoting oncology pharmaceutical safety. European Multidisciplinary Cancer Congress, September 23-27, 2011, Stockholm, Sweden.

57. Hashimoto K, Sasajima M, Ando M, Yonemori K, **Hirakawa A**, Tsuda H, Fujiwara Y. Molecular profiling as a possible prognostic marker for patients with cancer of unknown primary treated using platinum doublet chemotherapy. Annual Meeting, American Society of Clinical Oncology, June 3-7, 2011, Chicago, USA.

58. Harano K, Kojima Y, Hashimoto K, Ando M, **Hirakawa A**, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Makimoto A, Fujiwara. Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, d-actinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. Annual Meeting, American Society of Clinical Oncology, June 3-7, 2011, Chicago, USA.

59. Asano J, **Hirakawa A**. Covariate selection method in mixture cure model for survival data. Eastern North American Region/International Biometric Society, March 20-23, 2011, Miami, USA.

60. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, **Hirakawa A**, Shimizu C, Kinoshita, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y. Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity. 22nd International Congress on Anti Cancer Treatment, February 1-4, 2011, Paris, France.

61. Yamamoto H, Yonemori K, **Hirakawa A**, Shimizu C, Ando M, Katsumata N, Tamura K, Kinoshita T, Tsuda H, Fujiwara Y. Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy. European Society for Medical Oncology Congress, October 8-12, 2010, Milan, Italy.

62. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. 31th International Society of Clinical Biostatistics, August 29-September 2, 2010, Montpellier, France.

63. **Hirakawa A**, Hamada C, Yoshimura I. A practical comparison of response-adaptive randomizations in clinical trials with binary responses. 31th International Society of Clinical Biostatistics, August 29-September 2, 2010, Montpellier, France.

64. Hirata T, Yonemori K, Ando M, **Hirakawa A**, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma. 21st International Congress on Anti-cancer Treatment, February 1-5, 2010, Paris, France.

65. Kotani N, Katsumata N, Yonemori K, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Yunokawa M, Kouno T, Shimizu C, Tamura K, Fujiwara Y. Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer. The 10th Meeting of the International Society of Geriatric Oncology, October 15-17, 2009, Berlin, Germany.

66. Hashimoto K, Yonemori K, Shimizu C, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Fujiwara Y. Identification of clinical decision making factors in the treatment of geriatric patients with metastatic or recurrent breast cancer. The 10th Meeting of the International Society of Geriatric Oncology, October 15-17, 2009, Berlin, Germany.

67. Yonemori K, **Hirakawa A**, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registered clinical trials for cancer drug applications in Japan. The 10th Meeting of the International Society of Geriatric Oncology, October 15-17, 2009, Berlin, Germany.

68. Hirata T, Yonemori K, **Hirakawa A**, Kouno T, Shimizu C, Tamura K, Ando M, Katsumata N, Fujiwara Y. A retrospective comparison of pleural progression free survival between systemic therapy alone and pleurodesis followed by preceding systemic therapy in breast cancer patients with malignant pleural effusion. ASCO Breast Cancer Symposium, October 8-10, 2009, San Francisco, USA.

69. Hashimoto K, Yonemori K, Katsumata N, **Hirakawa A**, Shimizu C, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor marker in breast cancer patients without target lesion in first-line chemotherapy. ASCO Breast Cancer Symposium, October 8-10, 2009, San Francisco, USA.

70. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. 30th International Society of Clinical Biostatistics, August 23-27, 2009, Prague, Czech Republic.

71. **Hirakawa A**, Sato Y, Hamada C, Yoshimura I. An adjusted test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray experiments. XX IVth International Biometric Conference, July 13-19, 2008, Dublin, Republic of Ireland.

72. **Hirakawa A**, Sato Y, Hamada C, Yoshimura I. A test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray data analysis. 1st East Asia Regional Biometrics Conference, December 9-11, 2007, Tokyo, Japan.

73. **Hirakawa A**, Sato Y, Hamada C, Yoshimura I. A statistical method to estimate sensitivity and specificity for identifying marker genes with microarray data. 28th International Society of Clinical Biostatistics, July 29-August 2, 2007, Alexandroupolis, Greece.

74. **Hirakawa A**, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using a normal mixture distribution with microarray data. XX III International Biometric Conference, July 16-21, 2006, Montreal, Canada.

75. Sato Y, Ando H, **Hirakawa A**, Suganami H, Hamada C, Yoshimura I, Yoshida T, Yoshimura K. Multiple imputation method for SNP typing data in linkage disequilibrium mapping of polygenic traits. Joint Statistical Meetings, August 7-11, 2005, Minneapolis, USA.

＜国内学会・研究会発表＞

1. Kodama Y, Nishi M, Sato A, Imamura CK, Deguchi T, **Hirakawa A**, Kiyokawa N, Ohki K, Shima H, Kato K, Kato M, Kawasaki H, Sakaguchi H, Hiramatsu H, Goto H, Yamamoto S, Ito M, Tanizawa A, Yuza Y, Saito AM, Ogawa C, Taga T, Adachi S, Shimada H. Prospective study to evaluate the safety of ponatinib in pediatric patients with relapsed or refractory Philadelphia Chromosome-Positive Leukemia. Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) PedPona19 study. 第 85 回日本血液学会学術集会 2023 年 10 月 13-15 日, 東京都千代田区

2. 清水陽介, 佐藤宏征, 平川晃弘. 軸調整が非線形混合効果モデルのパラメータ推定に与える影響の検討. 2023 年度日本計量生物学会年会, 2023 年 4 月 21 日, 北海道札幌市

3. 平川晃弘. 感染症領域におけるプラットフォーム型臨床試験の有用性. 日本臨床試験学会第 14 回学術集会総会 2023 年 2 月 9 日, 石川県金沢市

4. 土屋輝一郎、長堀正和、花澤遼一、佐々木誠治、佐藤宏征、平川晃弘、安齋達彦、高橋邦彦、小林勇渡、日比谷秀爾、竹中健人、渡辺 守. アプリを用いた患者報告アウトカム PRO2 連日記録の臨床的意義 第 13 回日本炎症性腸疾患学会学術集会 2022 年 11 月 25 日, 大阪府大阪市

5. Tanaka H, Fukawa Y, Yamamoto K, Tanimoto K, Takemoto A, Hasumi H, **Hirakawa A**, Ishikawa Y, Fukuda S, Waseda Y, Yoshida S, Yokoyama M, Fujii Y. Renal parenchymal infiltration or micronodular spread in clear cell renal cell carcinoma: prognostic impact and genomic background. 第 110 回日本泌尿器科学会総会 2023 年 4 月 20-23 日, 兵庫県神戸市

6. Tsuchihashi K, Okuma H S, Machida R, Sadachi R, **Hirakawa A**, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Watanabe K, Sekine S, Okita N, Nakamura K, Yonemori K. A phase 2 trial of nivolumab monotherapy in rare cancer patients with mismatch repair deficiency or MSI-high: ROCK Trial (NCCH1709) a MASTER KEY sub-study. JSMO 2023 2023 年 3 月 16-18 日, 福岡県福岡市

7. 木下疫学会 2023 年 1 月日本人の農業従事者と農業以外の職業従事者におけるライフスタイルの比較〇木下 文恵 1、吉田 啓 1、藤谷 将也 1、今井 祐太 1、小林 由美子 1、伊藤 友哉 2、奥村 祐斗 2、佐藤 宏征 3、三上 達也 4、鄭 松伊 4、平川晃弘 3、中枌

昌弘 2

8. <u>平川晃弘</u>，佐藤宏征，花澤遼一，佐々木誠治，鈴木啓介．認知機能評価スケールの長期的変化を予測するアルゴリズムの開発．第 41 回日本認知症学会学術集会， 2022 年 11 月 25-27 日，東京都中央区

9. Nishikawa T, **Hirakawa A**, Kawashima S, Tomatsuri S, Nagasaka Y, Nakamura K, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yoshida H, Yonemori K. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma; Multicenter phase II investigator-initiated trial (STATICE TRIAL, NCCH1615) JSCO 2022 Frontier 2 2022 年 10 月 21 日，兵庫県神戸市

10. 上村悠，新井文子．Phase II Open-Label Study Evaluating JAK1/2 Inhibitor Ruxolitinib in Chronic Active Epstein - Barr Virus Infection．第 84 回日本血液学会学術集会．2022 年 10 月 14-16 日，福岡県福岡市

11. 上村夕香理，荒木康弘，安藤友紀，石黒智恵子，坂巻顕太郎，<u>平川晃弘</u>，柴田大朗．生物統計学的な観点からのワクチン開発における治験計画の立案の迅速化のための研究．第 12 回レギュラトリーサイエンス学会学術集会，2022 年 9 月 9 日　東京都千代田区，口演

12. 青山薫英，内山千代子，林滉一朗，徳田糸代，<u>平川晃弘</u>，山本幸夫，田村好拡，小林恒，村下公一，中路重之　日本の地域在住一般住民におけるデンタルフロスの使用習慣と歯周ポケット深さ・現在歯数との縦断的関連性　第 65 回秋季日本歯周病学会学術大会 2022 年 9 月 2－3 日，宮城県仙台市　ポスター展示

13. 高橋健太，温泉川真由，佐藤宏征，<u>平川晃弘</u>，小林康祐，金尾祐之，宮坂尚幸，野村弘行，青木大輔，横山良仁，竹原和宏．JGOG2043 における I-II 期子宮体癌を対象とした新しい再発予測モデルの再現性及び予測精度の検証　第 64 回日本婦人科腫瘍学会学術講演会，2022 年 7 月 14 日，福岡県久留米市

14. 北林 遼，野村 尚吾，佐藤 宏征，<u>平川晃弘</u>．バスケット試験における治療効果の類似度を考慮したベイズ流試験デザイン．2022 統計関連学会連合大会．2022 年 9 月 5 日，東京都武蔵野市（ハイブリッド開催）　口演

15. 太田 絵里，須藤 毅顕，中林 潤，Heewon Park，<u>平川晃弘</u>，木下 淳博，角 勇樹．臨床検査技師 AI 教育のためのクラウドコンピューター環境構築．第 16 回日本臨床検査学教育学会学術大会，2022 年 8 月 19 日，埼玉県日高市　口演

16. 佐立峻，<u>平川晃弘</u>，藤原武男.がん第 I 相試験における用量増減のリスクを考慮した

model-assisted デザインの提案，日本計量生物学会年会 2022 年 5 月 13 日，東京都葛飾区（ハイブリッド開催）　口演

17. 齊藤利雄，竹島泰弘，水野勝広，橋口昭大，佐橋健太郎，<u>平川晃弘</u>，川田洋充，勝野雅央．PRIME-SMA：脊髄性筋萎縮症患者を対象とした手の作業能力に対するリスジプラムの有効性評価方法に関する研究プロトコル，第 64 回日本小児神経学会学術集会，2022 年 6 月 2-5 日，群馬県高崎市

18. 橋口昭大，竹島泰弘，水野勝広，齊藤利雄，佐橋健太郎，<u>平川晃弘</u>，川田洋充，勝野雅央．SMA 患者の手の作業能力に対するリスジプラムの有効性評価方法：研究プロトコル，第 63 回日本神経学会学術大会，2022 年 5 月 20 日，東京都千代田区　口演

19. 中野梨香子，青山礼奈，曾根田ますみ，小峯万里，石山千明，山下直美，野口綾子，<u>平川晃弘</u>，佐藤宏征．A 病院集中治療部における身体拘束減少へ向けた適正化への取り組み＜看護師を対象とした 前向き調査より＞第 49 回日本集中治療医学会学術集会．2022 年 3 月 18-20 日，宮城県仙台市　口演

20. 須藤一起，清水俊雄，米盛勧，小山隆文，松井直子，神蔵将久，都祭紗和子，小島勇貴，大熊ひとみ，下井辰徳，野口瑛美，<u>平川晃弘</u>，佐立崚，沖田南都子，中村健一，山本昇，藤原康弘．MDM2 増幅を有する内膜肉腫を対象とした milademetan 単剤療法の医師主導治験 (NCCH1806/MK004)．第 19 回日本臨床腫瘍学会学術集会（JSMO 2022）．2022 年 2 月 19 日．京都府京都市　口演

21. 松本光史，西川忠曉，<u>平川晃弘</u>，川崎真美子，都祭紗和子，長坂優佳里，中村健一，長谷川幸清，森正彦，平嶋泰之，竹原和宏，有吉和也，加藤友康，柳下薫寛，濱田哲暢，吉田裕，米盛勧．Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma: STATICE TRIAL(NCCH1615)．第 19 回日本臨床腫瘍学会（JSMO 2022）．2022 年 2 月 17 日．京都府京都市　口演

22. 新妻邦泰，大沢伸一郎，遠藤英徳，出江紳一，安宅航太，<u>平川晃弘</u>，岩野政雄，冨永悌二．脳梗塞患者を対象とした他家 Muse 細胞製品 CL2020 の治療成績：ランダム化プラセボ対照二重盲検試験．日本脳神経外科学会第 80 回学術総会．2021 年 10 月 27-30 日．神奈川県横浜市．（2021 年 10 月 27 日 - 12 月 20 日．Web 開催）

23. 新垣誉子，小島勇貴，西川忠曉，大熊ひとみ，一村昌彦，沖田南都子，中村健一，<u>平川晃弘</u>，山本昇，米盛勧．切除不能胞巣状軟部肉腫に対する Atezolizumab の医師主導治験．JSMO 2021．2021 年 2 月 18-21 日．Web 開催．

24. <u>平川晃弘</u>．希少疾患領域の治験におけるベイズ流アプローチの利用可能性．AMED 医薬品等規制調和・評価研究事業合同シンポジウム，2020 年 12 月 8 日，Webinar．

25. <u>平川晃弘</u>．アダプティブデザインの理論と実践．日本計量生物セミナー，2019 年 11 月 14-15 日，東京都中央区．

26. <u>平川晃弘</u>．An experience of data sharing utilization．第 16 回 DIA 日本年会，2019 年 11 月 10-12 日，東京都江東区．

27. 平川晃弘．ランダム化対照試験．第 60 回日本小児血液・がん学会学術集会，2018 年 11 月 14-16 日，京都府左京区．

28. 平川晃弘．臨床研究における研究計画書作成の統計学的ポイント．第 33 回日本環境感染学会総会・学術集会，2018 年 2 月 23-24 日，東京都港区．

29. 平川晃弘．希少がん・希少フラクション領域の臨床開発オプションを考える．第 14 回 DIA 日本年会，2017 年 11 月 12-14 日，東京都江東区．

30. 平川晃弘．変化するがん第 1 相試験の役割．第 14 回 DIA 日本年会，2017 年 11 月 12-14 日，東京都江東区．

31. 平川晃弘．疾患レジストリデータを取り巻く規制案と現状．第 11 回 DIA 日本年会．2017 年 11 月 12-14 日，東京都江東区．

32. 志村将司，平川晃弘，五所正彦．中間解析を伴う臨床試験における条件付きバイアス調整推定量の性能評価．2017 年統計関連学会連合大会，2017 年 9 月 4-8 日，愛知県名古屋市．

33. 平川晃弘．新規抗がん剤と用量探索デザインの趨勢．2017 年統計関連学会連合大会，2017 年 9 月 4-8 日，愛知県名古屋市．

34. 平川晃弘，口羽文．希少がん臨床試験におけるベイズ流デザインの活用．日本計算機統計学会第 31 回大会，2017 年 5 月 10-12 日，東京都新宿区．

35. 平川晃弘．筋委縮性側索硬化症の病勢進行の統計的類型化．第 8 回生物統計ネットワーク，2017 年 3 月 27 日，福岡県福岡市．

36. Kakurai Y, **Hirakawa A**, Hamada C. Dose individualization based on multiple gene mutations for molecularly targeted agents. 日本計量生物学会年会，2017 年 3 月 16-17 日，東京都文京区．

37. 島村文也，平川晃弘，浜田知久馬．抗がん剤併用療法の第 I/II 相試験における 2 段階デザインを用いた用量探索．日本計量生物学会年会，2017 年 3 月 16-17 日，東京都文京区．

38. 佐藤宏征，平川晃弘，浜田知久馬．がん分子標的薬の用量探索法．日本計量生物学会年会，2017 年 3 月 16-17 日，東京都文京区．

39. 加藤凌輔，平川晃弘，浜田知久馬．抗がん剤第I相試験における経時データを使用した用量探索の方法に関する研究．日本計量生物学会年会，2017 年 3 月 16-17 日，東京都文京区．

40. 平川晃弘．MHLW のガイダンス後の論文レビュー．計量生物セミナー，2016 年 12 月 7 日，東京都中央区．

41. 平川晃弘．疾患レジストリを用いた医薬品開発の効率化．第 13 回 DIA 日本年会，2016 年 11 月 13-15 日，東京都江東区．

42. 平川晃弘．個別化医療を目指した先進的試験デザイン．第 13 回 DIA 日本年会，2016 年 11 月 13-15 日，東京都江東区．

43. Hirata T, Kawase Y, Kikuchi J, **Hirakawa A**, Okamoto S, Omori H, Nakatani Y, Ota H, Saigusa T, Miyake T, Kawamura I, Okubo M, Tsuchiya K, Matsuo H. The validation of the ischemic cut off of IFR and IFRa (During Hyperemia), to predict the ischemic threshold of FFR. 第 80 回日本循環器学会学術集会, 2016 年 3 月 18-20 日, 宮城県仙台市.

44. 倉田美穂, 柳澤昌実, <u>平川晃弘</u>, 神田善伸, 諫田淳也, 栗田尚樹, 鍬塚八千代, 松尾恵太郎, 一戸辰夫, 熱田由子. 一元管理登録（TRUMP） データを用いた Case Matched Control(1:k)抽出方法の検討. 日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

45. 清水 忍, 豊永亜希子, 細野恵美, 城田真里, 鈴木 哲, 末竹幸広, 平井寿子, 西村千穂, 田邊めぐみ, 小倉佳奈, 川影美千代, 安藤幸子, 鍬塚八千代, <u>平川晃弘</u>, 加藤勝義, 安藤昌彦, 水野正明, 片桐 渉, 日比英晴. 再生医療安全性確保法に基づく先進医療 B の臨床試験実施体制の構築について～骨髄由来間葉系細胞を用いた顎骨欠損に対する骨再生医療研究～. 日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

46. 中野春美, 中島智美, 永野優子, 山口真佐美, 土方靖浩, 鈴木啓介, 橋詰淳, 山田晋一郎, 稲垣智則, <u>平川晃弘</u>, 木下文恵, 勝野雅央, 祖父江元. 医師主導臨床試験における逸脱症例への多職種の対応と考察. 日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

47. <u>平川晃弘</u>, 木下文恵, 森由美子, 水野正明. 名古屋大学における医師主導臨床研究の統計解析支援業務に関する現状. 日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

48. <u>平川晃弘</u>, 木下文恵, 森由美子, 清水忍. 抗悪性腫瘍薬の臨床データパッケージ分析からみる今後の課題. 日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

49. <u>平川晃弘</u>. 多施設レジストリーデータは医薬品開発に活用できるか？日本臨床試験学会第 7 回学術集会総会, 2016 年 3 月 11-12 日, 愛知県名古屋市.

50. Hashimoto J, Koizumi F, Okuma H, **Hirakawa A**, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis, 第 13 回日本臨床腫瘍学会学術集会, 2015 年 7 月 16-18 日, 北海道札幌市.

51. <u>平川晃弘</u>. アカデミア研究における遺伝子探索. 第 12 回 DIA 日本年会, 2015 年 11 月 15-17 日, 東京都江東区.

52. <u>平川晃弘</u>. がん臨床試験の最近の動向と関連する統計的方法論. 第 6 回生物統計ネットワークシンポジウム, 2015 年 3 月 18 日, 東京都千代田区.

53. 金子周平, <u>平川晃弘</u>, 浜田知久馬. 遺伝子発現量データに基づく Lasso を用いた生存

時間予測モデルの構築に関する研究．日本計量生物学会年会，2015 年 3 月 12-13 日，京都府京都市．

54. <u>平川晃弘</u>，木下文恵，鍬塚八千代，室谷健太，森由美子，中村真由美，杉下明隆，清水忍，水野正明．中部先端医療開発円環コンソーシアムにおける Web 登録・割付システムの紹介．日本臨床試験学会第 6 回学術集会総会，2015 年 2 月 20-21 日，東京都文京区．

55. <u>平川晃弘</u>，清水忍，鍬塚八千代，室谷健太，木下文恵，中栃昌弘，杉下明隆，飯島祥彦，加藤勝義，安藤昌彦，水野正明．名古屋大学における臨床研究認定者制度に関する取組み．日本臨床試験学会第 6 回学術集会総会，2015 年 2 月 20-21 日，東京都文京区．

56. <u>平川晃弘</u>．がん第 I 相試験における用量探索法の最近の展開．科研費シンポジウム，2015 年 2 月 2-4 日，福岡県福岡市．

57. 島田和之，島田聡子，杉本慶樹，早川文彦，片山幸，<u>平川晃弘</u>，中村栄男，瀬戸加大，直江知樹，冨田章裕，清井仁．異種移植モデルを用いた血管内大細胞型 B 細胞リンパ腫の病態解析．第 76 回日本血液学会学術集会，2014 年 10 月 31-11 月 2 日，大阪府大阪市．

58. 浅野淳一，<u>平川晃弘</u>，浜田知久馬．Cox proportional hazards cure model により推定した治癒確率の予測精度の評価法．2014 年度統計関連学会連合大会，2014 年 9 月 13-16 日，東京都新宿区．

59. 清水忍，<u>平川晃弘</u>，鍬塚八千代，室谷健太，木下文恵，中栃昌弘，杉下明隆，飯島祥彦，加藤勝義，安藤昌彦，水野正明．名古屋大学における臨床研究認定者制度に関する取組み．ARO 協議会第 2 回学術集会，2014 年 9 月 23-24 日，京都府京都市．

60. 宮内理世，久保田誠司，伊藤善之，伊藤淳二，中原理絵，川村麻里子，岡田徹，長縄　慎二，吉川史隆，<u>平川晃弘</u>．名大病院における子宮頸癌術後の（化学）放射線療法による治療成績の検討．日本放射線腫瘍学会第 27 回学術大会，2014 年 12 月 11-13 日，神奈川県横浜市．

61. <u>平川晃弘</u>．広い視点を持った開発担当者・審査員を育てるために　〜境界を超えた人材育成と人材交流の必要性〜医療機関の立場から．第 11 回 DIA 日本年会，2014 年 11 月 16-18 日，東京都江東区．

62. 大篭友博，平野健一，小林和克，松本智宏，名取貴光，<u>平川晃弘</u>，今釜史郎，門松健治．ケラタン硫酸の欠損は ALS の早期病態形成を加速させる．Neuro 2013，2013 年 6 月 20-23 日，京都府京都市．

63. 　<u>平川晃弘</u>．FDA, EMA の M&S の公表事例と各規制当局の 動向．第 3 回レギュラトリーサイエンス学会学術大会，2013 年 11 月 3-4 日，東京都千代田区．

64. Nara E, Kodaira M, **Hirakawa A**, Noguchi E, Yamamoto H, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Risk factors of eribulin mesylate. 第 11 回日本臨床腫瘍学会学術集会，2013 年 8 月 29-31 日，宮城県仙台市．

65. 加倉井靖之, <u>**平川晃弘**</u>, 浜田知久馬. 抗がん剤併用療法第 I 相試験におけるコホート分割法に基づくベイズ流用量探索. 2013 年度日本計量生物学会, 2013 年 5 月 23-24 日, 福島県福島市.

66. <u>**平川晃弘**</u>. 分子標的治療の早期臨床試験：文献レビュー. 2012 年度科研費シンポジウム, 2013 年 3 月 22 日, 東京都品川区.

67. <u>**平川晃弘**</u>. 大規模ゲノムデータ解析における統計的課題：Gene signature を用いた予後診断法の開発を目指して. 2012 年度科研費シンポジウム, 2012 年 12 月 7-9 日, 名古屋.

68. 原野謙一, <u>**平川晃弘**</u>, 酒井瞳, 加藤隆之, 鈴木啓介, 渡辺幸子, 勝俣範之. DPC データを用いた卵巣がん初回化学療法における G-CSF 使用施設間格差の分析. 第 50 回日本癌治療学会学術集会, 2012 年 10 月 25-27 日, 神奈川県横浜市.

69. 谷山智子, 橋本堅治, <u>**平川晃弘**</u>, 勝俣範之, 公平誠, 米盛勧, 温泉川真由, 清水千佳子, 田村研治, 安藤正志, 藤原康弘. 標準化学療法抵抗となった患者の予後予測. 第 10 回日本臨床腫瘍学会学術集会, 2012 年 7 月 26-28 日, 大阪府大阪市.

70. 田辺裕子, 清水千佳子, <u>**平川晃弘**</u>, 友松純一, 公平誠, 温泉川真由, 米盛勧, 田村研治, 安藤正志, 藤原康弘. 化学療法による抹消神経障害の評価における知覚・痛覚定量分析装置（ペインビジョン）の有用性の検討. 第 20 回乳癌学会学術総会, 2012 年 6 月 28-30 日, 熊本県熊本市.

71. 金子周平, <u>**平川晃弘**</u>, 浜田知久馬. マイクロアレイデータを用いた Cox 回帰に基づく遺伝子選択. 2012 年度日本計量生物学会年会, 2012 年 5 月 25-26 日, 東京.

72. 渥美淳, <u>**平川晃弘**</u>, 浜田知久馬. 臨床試験で量的・質的な予後因子をバランスさせる割付方法. 2012 年度日本計量生物学会年会, 2012 年 5 月 25-26 日, 東京都立川市.

73. 斉藤真理, 龍島靖明, 米盛勧, <u>**平川晃弘**</u>, 西垣玲奈, 牧野好倫, 横手信昭, 安藤正志, 藤原康弘, 山本弘史. 製薬企業発行の抗がん剤患者説明用パンフレットの現状調査. 日本癌治療学会誌 抄録集, 2011; 46: 1054.

74. 原野謙一, 米盛勘, <u>**平川晃弘**</u>, 田辺裕子, 橋本淳, 公平誠, 橋本堅治, 友松純一, 温泉川真由, 清水千佳子, 田村研治, 勝俣範之, 安藤正志, 藤原康弘. 乳癌患者はどこで終末期医療を受けているか？日本癌治療学会誌 抄録集, 2011; 46: 660.

75. <u>**Hirakawa A**</u>, Hamada C. Sample size calculation for a regularized t-statistic in microarray experiments. 日本バイオインフォマティクス学会, 2011 年 11 月 8-10 日, 兵庫県神戸市.

76. Kaneko S, <u>**Hirakawa A**</u>, Hamada C. Gene selection using a high-dimensional Cox model in microarray data analysis. 日本バイオインフォマティクス学会, 2011 年 11 月 8-10 日, 兵庫県神戸市.

77. 斉藤真理, 龍島靖明, 米盛勧, <u>**平川晃弘**</u>, 西垣玲奈, 牧野好倫, 横手信昭, 安藤正志, 藤原康弘, 山本弘史. 製薬企業発行の抗がん剤患者説明用パンフレットの現状調査. 第 49 回 日本癌治療学会学術集会, 2011 年 10 月 27-29 日, 愛知県名古屋市.

78. Hashimoto K, Sasajima Y, Ando M, Yonemori K, <u>**Hirakawa A**</u>, Kodaira M, Tomomatsu J,

Yunokawa M, Shimizu C, Tamura K, Katsumata N, Tsuda H, Fujiwara Y. Molecular profiling (MP) as a possible prognostic marker for patients with cancer of unknown primary (CUP) treated using platinum doublet (PD) chemotherapy. 第 9 回 日本臨床腫瘍学会学術集会, 2011 年 7 月 21-23 日, 神奈川県横浜市.

79. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, **Hirakawa A**, Shimizu C, Kinoshita T, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y. Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity. 第 9 回 日本臨床腫瘍学会学術集会, 2011 年 7 月 21-23 日, 神奈川県横浜市.

80. 平川晃弘. マイクロアレイデータにおける調整統計量に基づくサンプルサイズ設計. 科研費シンポジウム, 2010 年 3 月 26 日, 東京都江東区.

81. 平川晃弘, 佐藤泰憲, 浜田知久馬, 吉村功. マイクロアレイデータにおける発現変動遺伝子同定のための縮小推定量に基づく統計量の提案. 科研費シンポジウム, 2008 年 2 月 28-29 日, 東京都新宿区.

82. 平川晃弘, 佐藤泰憲, 寒水孝司, 浜田知久馬, 吉村功. マイクロアレイデータにおける FDR に基づくカットオフ値の選定法. 第 5 回東京理科大学医薬統計フォーラム, 2007 年 10 月 27 日, 東京都新宿区.

83. 平川晃弘, 佐藤泰憲, 寒水孝司, 浜田知久馬, 吉村功. マイクロアレイデータにおける疾患感受性遺伝子の同定法に関する統計学的検討. 第 65 回日本癌学会学術総会, 2006 年 9 月 28-30 日, 神奈川県横浜市.

84. 平川晃弘, 佐藤泰憲, 寒水孝司, 浜田知久馬, 吉村功. マイクロアレイデータにおける FDR に基づくカットオフ値の選定方法に関する検討. 統計関連学会連合大会, 2006 年 9 月 5-8 日, 宮城県仙台市.

85. 平川晃弘, 佐藤泰憲, 寒水孝司, 浜田知久馬, 吉村功. マイクロアレイデータにおける混合正規分布を用いた FDR の推定法. 計量生物学会シンポジウム, 2006 年 5 月 25-26 日, 埼玉県和光市.

講演

1. 平川晃弘. 早期用量探索試験のデザインの変遷. 日本計量生物講演会, 2023 年 7 月 31 日, 東京都新宿区

2. 平川晃弘. リアルワールドデータを用いた次世代の臨床試験デザイン. 日本婦人科腫瘍学会（第 65 回）, 2023 年 7 月 14-16 日, 島根県松江市

3. 平川晃弘. 臨床試験方法論のパラダイムシフト: プラットフォーム試験の有用性. 第 50 回日本集中治療医学会 2023 年 3 月 2-4 日, 京都府京都市

4. 平川晃弘. 希少疾患に対する治療効果の定量化についての一考察. JPMA「Rare disease

の臨床開発における治療効果推測の現状と課題」シンポジウム．2023 年 2 月 20 日，
東京都中央区

5. 平川晃弘．ランダム化比較試験の中間解析： がん領域のプラクティス．日本計量生物
セミナー， 2022 年 12 月 8-9 日，東京都文京区．

6. 平川晃弘．マスタープロトコル試験．日本臨床試験学会第 13 回学術集会総会，2022 年
2 月 4 日(金)，東京都千代田区．

7. 平川晃弘．マスタープロトコルを用いた臨床試験：医薬品開発の効率化と加速化を目
指して．DIA Master Protocol Workshop 2021, 2021 年 5 月 18 日(火), Web 開催．

8. 平川晃弘．希少がん・希少フラクション領域の臨床試験デザイン・統計解析の最前線．
第 3 回日本サルコーマ治療研究学会学術集会，2020 年 2 月 21-22 日，大阪府大阪市．

9. 平川晃弘．医薬品開発・臨床研究における疾患レジストリの活用の実際．第 33 回日本
計算機統計学会，2019 年 11 月 30 日-12 月 1 日，東京都渋谷区．

10. **Hirakawa A**. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: application to basket trial data. 6th International Society of Biopharmaceutical Statistics. August 26-30, 2019, Kyoto, Japan.

11. **Hirakawa A**. Single-pivotal basket trials for rare cancer development in Japan. 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18-20, 2019, Kyoto, Japan.

12. **Hirakawa A**. A clustering-based basket design. 3rd Pacific Rim Cancer Biostatistics Workshop, June 27-28, 2019, Portland.

13. **Hirakawa A**. Adaptive Designs in Clinical Trials. ICPM 2018: 20th International Conference on Psychosomatic Medicine，September 27-28，2018，Tokyo.

14. 平川晃弘, Precision Medicine を目指した適応的デザイン―バスケットデザインの理論
と実践―. 2018 年度計量生物学会年会チュートリアル, 2018 年 3 月 29-30 日，東京都立
川市．

15. 平川晃弘．臨床研究における研究計画書作成の統計学的ポイント．第 33 回日本環境感
染学会総会・学術集会，2018 年 2 月 23-24 日，東京都港区．

16. 平川晃弘．臨床試験におけるデータモニタリング委員会の役割と責務．ARO 協議会第 5
回生物統計セミナー, 2018 年 2 月 3 日，東京都千代田区．

17. 平川晃弘，ベイズ流接近法の臨床研究への応用．医学統計研究会定例シンポジウム
2017, 2017 年 10 月 28 日，東京都渋谷区．

18. **Hirakawa A**. Two-stage dose and zone finding method for two agent combination phase 1/2 trials. Pacific Rim Cancer Biostatistics Workshop, October 12-13, 2017， Kanazawa.

19. 平川晃弘．アカデミア臨床試験におけるデータモニタリング委員会の役割と責務．ARO
協議会第 5 回学術集会, 2017 年 9 月 25-27 日，愛知県名古屋市．

20. 平川晃弘．患者レジストリ活用の動向．AMED シンポジウム 2017, 2017 年 5 月 29-30 日，
東京都千代田区．

21. **Hirakawa A**. Statistical Consideration for Novel Dose Escalation Methods in Phase 1 Oncology Trials. 2nd NCCH Workshop. 23 July, 2017, Tokyo.

22. 平川晃弘. 医療統計を学会発表や論文作成に役立てる. 第 25 回日本心血管インターベンション治療学会（CVIT2017），2017 年 7 月 5-7 日，京都.

23. 平川晃弘. コメディカルのためのわかりやすい医療統計学. 第 24 回日本心血管インターーベンション治療学会（CVIT2016），2016 年 7 月 7-9 日，東京.

24. 平川晃弘，口羽文. 希少がん臨床試験におけるベイズ流デザインの活用. 日本計算機統計学会第 31 回大会. 2017 年 5 月 10-12 日，東京都新宿区.

25. 平川晃弘. 筋委縮性側索硬化症の病勢進行の統計的類型化. 第 8 回生物統計ネットワーク，2017 年 3 月 27 日，福岡県福岡市.

26. 平川晃弘. 頻度流標本サイズ設定. ARO 協議会第 3 回生物統計セミナー，2016 年 1 月 30 日，大阪府大阪市.

27. 平川晃弘. がん第 1 相試験における用量探索法の変遷（日本計量生物学会奨励賞受賞者講演）. 2016 年度統計関連学会連合大会，2016 年 9 月 4-7 日，石川県金沢市.

28. 平川晃弘. がん臨床試験デザインの最前線：早期探索デザインを中心に. 平成 28 年度 JMTO 臨床試験ワークショップ，2016 年 6 月 18 日，愛知県名古屋市.

29. 平川晃弘. コメディカルのためのわかりやすい医療統計学. 第 24 回日本心血管インターーベンション治療学会（CVIT2016），2016 年 7 月 7-9 日，東京.

30. 平川晃弘. 医薬品開発におけるバイオマーカーの活用，PhUSE 2015，2015 年 12 月 3 日，東京.

31. 平川晃弘. 臨床試験で必要となる統計学〜その考え方とは〜，第 33 回日本神経治療学会総会，2015 年 11 月 26-28 日，名古屋.

32. 平川晃弘. 筋萎縮性側索硬化症の国内観察研究とその課題，医学統計シンポジウム，2015 年 10 月 24 日，東京.

33. 平川晃弘. 頻度流標本サイズ設定. ARO 協議会第 3 回学術集会，2015 年 9 月 18-19 日，東京都文京区.

34. 平川晃弘. コメディカルが知っておくべき医療統計学. 第 23 回日本心血管インターーベンション治療学会（CVIT2015），2015 年 7 月 30 日-8 月 1 日，福岡.

35. **Hirakawa A**. Dose-finding designs for combination therapies in oncology. Pacific Rim Cancer Biostatistics Workshop, August 14-15, 2015, Seattle.

36. 平川晃弘. 臨床試験デザインの統計的経験則. 医学統計シンポジウム，2015 年 6 月 20 日，東京.

37. 平川晃弘. がん臨床試験の最近の動向と関連する統計的方法論. 第 6 回生物統計ネットワークシンポジウム，2015 年 3 月 18 日，東京.

38. 平川晃弘. がん第 I 相試験における用量探索法の最近の展開. 科研費シンポジウム， 2015 年 2 月 2-4 日，福岡県福岡市.

39. <u>平川晃弘</u>．良い論文を書くための統計学．東海ライブ研究会，第 4 回豊橋ライブデモンストレーションコース，2014 年 5 月 30-31 日，愛知県豊橋市．

40. <u>平川晃弘</u>．抗がん剤開発における早期臨床試験の現状と課題．医学統計ｼﾝﾎﾟｼﾞｳﾑ，2014 年 12 月 1 日，東京都．

41. <u>平川晃弘</u>．抗がん医薬品の開発における早期臨床試験の現状．大分統計談話会，2013 年 10 月 10-11 日，大分県大分市．